Purification of recombinant iduronate 2-sulfatase

A simplified chromatography process for purifying recombinant I2S proteins improves bioavailability by retaining Cα-formylglycine, addressing inefficiencies in existing methods and ensuring high purity for effective enzyme replacement therapy.

JP7594365B2Active Publication Date: 2024-12-04TAKEDA PHARMA CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2020037811
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2012-06-29
Filing Date
2020-03-05
Publication Date
2024-12-04
Estimated Expiration
2033-06-28

AI Technical Summary

Technical Problem

Current methods for purifying recombinant iduronate-2-sulfatase (I2S) proteins for enzyme replacement therapy in Hunter syndrome are inefficient, requiring six chromatography columns and not ensuring high retention of the Cα-formylglycine (FGly) form, which is crucial for enzyme activity and bioavailability.

Method used

A streamlined purification process using fewer than six chromatography steps, including anion exchange, cation exchange, mixed mode, and hydrophobic interaction chromatography, to achieve high retention of Cα-formylglycine in recombinant I2S proteins, ensuring compliance with commercial purification requirements and improved bioavailability.

Benefits of technology

The process achieves high purity and bioavailability of recombinant I2S proteins, with over 70% conversion of cysteine to Cα-formylglycine, meeting commercial standards and enhancing therapeutic efficacy for Hunter syndrome treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007594365000027
    Figure 0007594365000027
  • Figure 0007594365000028
    Figure 0007594365000028
  • Figure 0007594365000029
    Figure 0007594365000029
Patent Text Reader

Abstract

To provide purification of recombinant iduronate-2-sulfatase.SOLUTION: The invention provides, among other things, an improved method for purifying I2S protein produced by recombination for enzyme replacement therapy. The invention is, in part, based on a surprising discovery that the recombinant I2S protein can be purified from unprocessed biomaterials such as a cell culture medium containing I2S by using as few as four chromatography columns. Approved existing purification process of recombinant I2S for enzyme replacement therapy involves six chromatography columns.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 61 / 666,733, filed June 29, 2012, which is incorporated herein by reference in its entirety.

[0002] Sequence Listing The present specification refers to a Sequence Listing that was submitted in electronic format as an ASCII text file entitled "2006685-0342_SEQ_LIST" on Jun. 27, 2013. The text file was generated on Jun. 25, 2013 and is 15 KB in size. The entire contents of the Sequence Listing are incorporated herein by reference. [Background technology]

[0003] Mucopolysaccharidosis type II (MPSII, Hunter syndrome) is an X-linked recessive lysosomal storage disorder resulting from a deficiency of the enzyme iduronate-2-sulfatase (I2S). I2S cleaves terminal 2-O-sulfate moieties from the glycosaminoglycans (GAGs) dermatan sulfate and heparan sulfate. Missing or defective I2S in patients with Hunter syndrome leads to the progressive accumulation of GAGs in the lysosomes of various cell types, causing cellular enlargement, organ hypertrophy, tissue destruction, and organ system failure.

[0004] Generally, the physical manifestations of people with Hunter syndrome include both physical and neuronal symptoms. For example, in some cases of Hunter syndrome, central nervous system involvement leads to developmental delay and neurological problems. The non-neuronal manifestations of Hunter syndrome, while not usually present at birth, can have dramatic effects on the peripheral tissues of the body over time due to the progressive accumulation of GAGs in the body's cells. The accumulation of GAGs in the peripheral tissues leads to a distinctive coarseness in the facial features of patients, resulting in a protruding forehead, flat nasal bridge and enlarged tongue, which are hallmarks of Hunter syndrome. Similarly, the accumulation of GAGs can adversely affect the organ systems of the body. Early manifestations include thickening of the walls of the heart, lungs and airways, and abnormal enlargement of the liver, spleen and kidneys; these significant changes can ultimately lead to widespread catastrophic organ failure. As a result, Hunter syndrome is always severe, progressive and life-limiting.

[0005] Enzyme replacement therapy (ERT) is an approved therapy for treating Hunter syndrome (MPSII) and involves administering exogenous replacement I2S enzyme to patients with Hunter syndrome. Summary of the Invention [Means for solving the problem]

[0006] The present invention provides, among other things, an improved method for purifying recombinantly produced I2S protein for enzyme replacement therapy. The present invention can purify recombinant I2S protein from raw biological material, such as cell culture media, containing I2S, using a process involving as few as four chromatography columns. Existing approved purification processes for enzyme replacement therapy of recombinant I2S involve six chromatography columns. As described in the Examples section, recombinant I2S protein purified using the four column process described in the present invention complies with commercial purification requirements in the United States and many other countries. Furthermore, recombinant I2S enzyme purified according to the present invention has a high rate of C α-formylglycine (FGly) (e.g., greater than 70%, up to 100%), and unique features such as sialic acid content and glycan map that are important for the activity of the I2S enzyme and may promote bioavailability and / or lysosomal targeting of the recombinant I2S protein. Thus, the present invention provides an effective, inexpensive and fast process for purifying recombinant I2S protein. The present invention is particularly useful for purifying recombinant I2S protein produced in serum-free medium.

[0007] Thus, in one aspect, the present invention provides a method for purifying recombinant I2S protein from impure preparations using a process based on one or more of anion exchange chromatography, cation exchange chromatography, mixed mode chromatography, and hydrophobic interaction chromatography. In some embodiments, the inventive method described in the present invention involves fewer than six (e.g., fewer than five, fewer than four, or fewer than three) chromatography steps. In some embodiments, the inventive method described in the present invention involves two, three, four, or five chromatography steps. In some embodiments, the inventive method described in the present invention involves four chromatography steps. In some embodiments, the purified recombinant I2S protein of the present invention contains less than 100 ng / mg host cell protein (HCP) (e.g., less than 90 ng / mg HCP, less than 80 ng / mg HCP, less than 70 ng / mg HCP, less than 60 ng / mg HCP, less than 50 ng / mg HCP, less than 40 ng / mg HCP, less than 30 ng / mg HCP, less than 20 ng / mg HCP, less than 10 ng / mg HCP).

[0008] In some embodiments, the suitable anion exchange chromatography is Q chromatography. In some embodiments, the suitable cation exchange chromatography is SP chromatography. In some embodiments, the suitable mixed mode chromatography is hydroxyapatite (HA) chromatography. In some embodiments, the suitable hydrophobic interaction chromatography is phenyl chromatography.

[0009] It is understood that anion exchange chromatography (e.g., O column), cation exchange chromatography (e.g., SP column), mixed mode chromatography (e.g., HA column), and hydrophobic interaction chromatography (e.g., phenyl column) can be performed in any order. In some embodiments, the method according to the present invention is performed in the order of anion exchange chromatography (e.g., O column), cation exchange chromatography (e.g., SP column), mixed mode chromatography (e.g., HA column), and hydrophobic interaction chromatography (e.g., phenyl column).

[0010] In some embodiments, the impure preparation or intermediate eluate or flow-through fraction is adjusted to a pH of about 5.0-7.0 (e.g., about 5.0, 5.5, 6.0, 6.5 or 7.0) and a conductivity of about 10-20 mS / cm (e.g., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 mS / cm) before being loaded onto an anion exchange chromatography column (e.g., a Q column). In some embodiments, the pH is adjusted using 1 M sodium acetate. In some embodiments, the conductivity is adjusted using 5 M sodium chloride. In some embodiments, the anion exchange chromatography column, once loaded, is washed with a wash buffer containing a salt (e.g., NaCl) at a concentration of about 140 mM to 200 mM (e.g., about 140 mM, 145 mM, 150 mM, 155 mM, 160 mM, 165 mM, 170 mM, 175 mM, 180 mM, 185 mM, 190 mM, 195 mM, or 200 mM) and a pH of about 5.0 to 7.0 (e.g., about 5.0, 5.5, 6.0, 6.5, or 7.0). In some embodiments, the anion exchange chromatography column is eluted with an elution buffer containing a linear salt (e.g., NaCl) gradient. In some embodiments, a suitable linear NaCl gradient comprises a range of about 0-500 mM NaCl (e.g., about 0-400 mM, about 0-350 mM, about 0-300 mM, about 50-500 mM, about 150-500 mM, about 150-450 mM, about 150-400 mM).

[0011] In some embodiments, the impure preparation or intermediate eluate or flow-through fraction is adjusted to a conductivity in the range of about 1 mS / cm to 20 mS / cm (e.g., about 1 mS / cm to 15 mS / cm, about 1 mS / cm to 10 mS / cm, about 1 mS / cm to 8 mS / cm, about 1 mS / cm to 6 mS / cm, about 1 mS / cm to 4 mS / cm, about 2 mS / cm to 4 mS / cm) before being loaded onto a cation exchange chromatography column (e.g., an SP column). In some embodiments, the impure preparation or intermediate eluate or flow-through fraction is adjusted to a conductivity in the range of about 2 mS / cm to 4 mS / cm (e.g., 2, 2.5, 3, 3.5, or 4 mS / cm) before being loaded onto a cation exchange chromatography column (e.g., an SP column). In some embodiments, the conductivity is adjusted by diluting the eluate from the anion exchange chromatography column with HO in a ratio of about 1-2:1 (e.g., 1:1, 1.1:1, 1.2:1, 1.3:1, 1.4:, 1.5:1, 1.6:1, 1.7:1, 1.8:1, 1.9:1, or 2:1). In some embodiments, the conductivity is adjusted by diafiltration. In some embodiments, the cation exchange chromatography column is operated at a pH of about 5.0-6.5 (e.g., 5.0, 5.5, 6.0, or 6.5). In some embodiments, the cation exchange chromatography column is operated with a buffer containing a phosphate (e.g., NaPO4) concentration in the range of about 0.01 M to about 0.1 M (e.g., about 0.01 M, 0.02 M, 0.03 M, 0.04 M, 0.05 M, 0.06 M, 0.07 M, 0.08 M, 0.09 M, or 0.1 M). In some embodiments, a suitable pH is about 5.0 to 6.5 (e.g., about 5.0, 5.5, 6.0, or 6.5).

[0012] In some embodiments, the impure preparation or intermediate eluate or flow-through is adjusted to a phosphate (e.g., NaPO4) concentration in the range of about 0.001M to about 0.01M (e.g., about 0.001M, 0.002M, 0.003M, 0.004M, 0.005M, 0.006M, 0.007M, 0.008M, 0.009M, or 0.01M), a pH of about 5.0 to 6.5 (e.g., about 5.0, 5.5, 6.0, or 6.5) before being loaded onto a mixed-mode chromatography column (e.g., an HA column). In some embodiments, the mixed-mode chromatography column (e.g., an HA column), once loaded, is washed with a wash buffer having phosphate (e.g., 1 to 10 mM sodium or potassium phosphate) at or near neutral pH. In some embodiments, the mixed mode chromatography column (e.g., an HA column) is washed with a wash buffer having a phosphate concentration in the range of about 10-20 mM (e.g., about 10-18 mM, 10-16 mM, 10-15 mM, 12-20 mM, 14-18 mM, 14-16 mM). In some embodiments, the mixed mode chromatography column (e.g., an HA column) is washed with a wash buffer having a phosphate concentration of greater than 10 mM, 11 mM, 12 mM, 13 mM, 14 mM, 15 mM, 16 mM, 17 mM, 18 mM, 19 mM, 20 mM. In some embodiments, elution from the mixed mode chromatography column (e.g., an HA column) is accomplished with a gradient phosphate buffer. In some embodiments, a suitable elution buffer may have a gradient of sodium or potassium phosphate of about 1-400 mM (e.g., 1-300 mM, 1-200 mM, 1-150 mM, 1-100 mM, 10-350 mM, 10-300 mM, 10-250 mM, 10-200 mM, 10-150 mM, 10-140 mM, 10-130 mM, 10-120 mM, 10-110 mM, 10-100 mM, 10-90 mM, 10-80 mM, 10-70 mM, 10-60 mM, 10-50 mM). In some embodiments, elution from the HA column is achieved by stepwise increasing the concentration of phosphate in the elution buffer.In some embodiments, the stepwise elution buffer may have a phosphate (e.g., sodium phosphate) concentration selected from 10 mM, 20 mM, 30 mM, 40 mM, 50 mM, 60 mM, 70 mM, 80 mM, 90 mM, 100 mM, 110 mM, 120 mM, 130 mM, 140 mM, 150 mM, 200 mM, 250 mM, 300 mM, 350 mM, 400 mM. In some embodiments, elution from a mixed-mode chromatography column (e.g., an HA column) is accomplished with an elution buffer having a concentration of phosphate (e.g., sodium phosphate) in the range of about 50 mM to 150 mM (e.g., selected from 50 mM, 60 mM, 70 mM, 80 mM, 90 mM, 100 mM, 110 mM, 120 mM, 130 mM, 140 mM, 150 mM, and combinations thereof of phosphate (e.g., sodium phosphate)).

[0013] In some embodiments, the impure preparation or intermediate eluate or flow-through fraction is adjusted to a salt (e.g., NaCl) concentration in the range of about 0.5M to about 2.0M (e.g., about 0.5M, 1.0M, 1.1M, 1.2M, 1.3M, 1.4M, 1.5M, 1.6M, 1.7M, 1.8M, 1.9M, or 2.0M NaCl), a pH in the range of about 4.5 to 6.0 (e.g., about 4.5, 5.0, 5.5, or 6.0) prior to being loaded onto a hydrophobic interaction chromatography column (e.g., a phenyl column). In some embodiments, the hydrophobic interaction chromatography column, once loaded, is washed with a wash buffer containing a salt (e.g., NaCl) at a concentration ranging from about 0.5M to 2.0M (e.g., about 0.5M, 1.0M, 1.1M, 1.2M, 1.3M, 1.4M, 1.5M, 1.6M, 1.7M, 1.8M, 1.9M, or 2.0M NaCl) and a pH of about 4.5 to 6.0 (e.g., about 4.5, 5.0, 5.5, or 6.0). In some embodiments, the hydrophobic interaction chromatography column is eluted with a wash buffer containing a salt (e.g., NaCl) at a concentration ranging from 0.1 M to about 0.5 M (e.g., about 0.1 M, 0.2 M, 0.3 M, 0.4 M, or 0.5 M NaCl) and a pH of about 4.5 to 6.0 (e.g., about 4.5, 5.0, 5.5, or 6.0).

[0014] In some embodiments, the column height of each of the anion exchange chromatography, cation exchange chromatography, mixed mode chromatography, and hydrophobic interaction chromatography is in the range of 14-25 cm (e.g., 15-25 cm, 15-20 cm, 14-24 cm, 14-22 cm, 14-20 cm, or 16-18 cm). In some embodiments, the column height of each of the anion exchange chromatography, cation exchange chromatography, mixed mode chromatography, and hydrophobic interaction chromatography is about 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 cm.

[0015] In some embodiments, the inventive method described in the present invention comprises a step of viral inactivation before loading the impure preparation onto the first chromatography column. In some embodiments, the viral inactivation step comprises adding a detergent to the impure preparation. In some embodiments, the inventive method described in the present invention further comprises a step of removing viruses after the last chromatography column. In some embodiments, the inventive method further comprises a step of ultrafiltration and / or diafiltration. In some embodiments, the ultrafiltration and / or diafiltration step comprises exchanging the purified recombinant I2S protein into a drug formulation buffer.

[0016] In some embodiments, the invention is used to purify a recombinant I2S protein having an amino acid sequence at least about 50% (e.g., at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%) identical to SEQ ID NO: 1. In some embodiments, the invention is used to purify a recombinant I2S protein having an amino acid sequence identical to SEQ ID NO: 1.

[0017] In some embodiments, the present invention is used to purify recombinant I2S protein produced by mammalian cells cultured in suspension in serum-free medium. In some embodiments, a serum-free medium suitable for the present invention is devoid of animal-derived components. In some embodiments, a serum-free medium suitable for the present invention is a chemically defined medium. In some embodiments, the mammalian cells are cultured in a bioreactor. In some embodiments, the mammalian cells co-express recombinant I2S protein and formylglycine generating enzyme (FGE). In some embodiments, the mammalian cells are human cells.

[0018] In some embodiments, the impure preparation used in the methods of the invention is prepared from serum-free medium containing recombinant I2S protein secreted from mammalian cells, hi some embodiments, the impure preparation used in the methods of the invention is thawed from a frozen medium preparation.

[0019] In some embodiments, a purified recombinant I2S protein of the invention contains, on average, 16-22 (e.g., 16-21, 16-20, 16-19, 17-22, 17-21, 17-20, 17-19) sialic acids per molecule. In some embodiments, a purified recombinant I2S protein of the invention contains, on average, 16, 17, 18, 19, 20, 21, or 22 sialic acids per molecule.

[0020] In some embodiments, a purified recombinant I2S protein of the invention has at least about 70% (e.g., at least 77%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%) conversion of the cysteine ​​residue corresponding to Cys59 of human I2S (SEQ ID NO:1) to Cα-formylglycine (FGly). In some embodiments, a purified recombinant I2S protein of the invention has substantially 100% conversion of the cysteine ​​residue corresponding to Cys59 of human I2S (SEQ ID NO:1) to Cα-formylglycine (FGly). In some embodiments, a purified recombinant I2S protein of the invention has a specific activity of at least about 20 U / mg, 30 U / mg, 40 U / mg, 50 U / mg, 60 U / mg, 70 U / mg, 80 U / mg, 90 U / mg, or 100 U / mg as determined by an in vitro sulfate release activity assay using heparin disaccharide as a substrate.

[0021] In some embodiments, the purified recombinant I2S protein of the invention is characterized by greater than 70%, 75%, 80%, 85%, 90%, 95% cellular uptake as determined by an in vitro uptake assay.

[0022] In some embodiments, the purified recombinant I2S protein of the invention is characterized by a glycan map comprising seven peak groups, each of which indicates neutral (peak group 1), monosialylated (peak group 2), disialylated (peak group 3), monophosphorylated (peak group 4), trisialylated (peak group 5), tetrasialylated (peak group 6), or diphosphorylated (peak group 7) I2S protein. In some embodiments, the glycan map is generated after neuraminidase digestion. In other embodiments, the glycan map is generated after alkaline phosphatase digestion.

[0023] The present invention provides, among other things, purified recombinant I2S protein, and pharmaceutical compositions or formulations comprising the same, as described herein. In some embodiments, the formulations are formulated for intravenous, subcutaneous, and / or intrathecal administration. The present invention also provides a method for treating Hunter syndrome by administering purified recombinant I2S, pharmaceutical compositions or formulations comprising the same to a subject in need of treatment.

[0024] As used herein, the terms "I2S protein," "I2S," "I2S enzyme," or grammatical equivalents, unless otherwise indicated, refer to the preparation of recombinant I2S protein molecules.

[0025] As used in this application, the terms "about" and "approximately" are used as equivalents. Numbers used in this application, with or without about / approximately, are meant to include normal increases or decreases recognized by one of ordinary skill in the relevant art.

[0026] Other features, objects, and advantages of the present invention will become apparent from the following detailed description. However, it should be understood that the detailed description, while illustrating embodiments of the present invention, is for illustrative purposes only and is not meant to be limiting. Various changes or modifications within the scope of the present invention will become apparent to those skilled in the art from the detailed description. The present invention also provides the following: (Item 1) 1. A composition comprising a purified recombinant iduronate-2-sulfatase (I2S) having an amino acid sequence at least 70% identical to SEQ ID NO:1, wherein the purified recombinant I2S converts at least about 70% of the cysteine ​​residue corresponding to Cys59 in SEQ ID NO:1 to Cα-formylglycine (FGly), and further, the purified recombinant I2S contains less than 150 ng / mg of host cell protein (HCP). (Item 2) 2. The composition of claim 1, wherein the purified recombinant I2S contains less than 100 ng / mg HCP. (Item 3) 2. The composition of claim 1, wherein the purified recombinant I2S contains less than 80 ng / mg HCP. (Item 4) 2. The composition of claim 1, wherein the purified recombinant I2S contains less than 60 ng / mg HCP. (Item 5) A composition comprising a purified recombinant iduronate-2-sulfatase (I2S) having an amino acid sequence at least 70% identical to SEQ ID NO:1, wherein the purified recombinant I2S converts at least about 70% of the cysteine ​​residue corresponding to Cys59 in SEQ ID NO:1 to Cα-formylglycine (FGly), and further, the purified recombinant I2S contains, on average, at least 16 sialic acids per molecule. (Item 6) 6. The composition of claim 5, wherein the purified recombinant I2S contains, on average, at least 18 sialic acids per molecule. (Item 7) 6. The composition of claim 5, wherein the purified recombinant I2S contains, on average, at least 20 sialic acids per molecule. (Item 8) A composition comprising a purified recombinant iduronate-2-sulfatase (I2S) having an amino acid sequence at least 70% identical to SEQ ID NO:1, wherein the purified recombinant I2S converts at least about 70% of the cysteine ​​residue corresponding to Cys59 in SEQ ID NO:1 to Cα-formylglycine (FGly), and further, the purified recombinant I2S contains at least 10% bis-phosphorylated oligosaccharides per enzyme. (Item 9) 9. The composition of claim 8, wherein the purified recombinant I2S contains at least 20% bis-phosphorylated oligosaccharides per enzyme. (Item 10) 1. A composition comprising a purified recombinant iduronate-2-sulfatase (I2S) having an amino acid sequence at least 70% identical to SEQ ID NO:1, wherein the purified recombinant I2S has at least about 70% conversion of a cysteine ​​residue corresponding to Cys59 of SEQ ID NO:1 to Cα-formylglycine (FGly); and, further, the purified recombinant I2S is characterized by a glycan map comprising seven or fewer peak groups selected from peak groups indicating neutral (Peak Group 1), monosialylated (Peak Group 2), disialylated (Peak Group 3), monophosphorylated (Peak Group 4), trisialylated (Peak Group 5), tetrasialylated (Peak Group 6), or diphosphorylated (Peak Group 7) I2S protein. (Item 11) The composition of any one of the preceding items, wherein the purified recombinant I2S converts the cysteine ​​residue corresponding to Cys59 in SEQ ID NO:1 to Cα-formylglycine (FGly) by at least about 75%. (Item 12) 11. The composition of any one of items 1 to 10, wherein the purified recombinant I2S converts the cysteine ​​residue corresponding to Cys59 of SEQ ID NO:1 to Cα-formylglycine (FGly) by at least about 80%. (Item 13) A composition comprising a purified recombinant iduronate-2-sulfatase (I2S) having an amino acid sequence at least 70% identical to SEQ ID NO:1, wherein the purified recombinant I2S comprises greater than about 85% conversion of the cysteine ​​residue corresponding to Cys59 in SEQ ID NO:1 to Cα-formylglycine (FGly). (Item 14) 14. The composition of claim 13, wherein the purified recombinant I2S contains greater than about 90% conversion of the cysteine ​​residue corresponding to Cys59 of SEQ ID NO:1 to Cα-formylglycine (FGly). (Item 15) 14. The composition of claim 13, wherein the purified recombinant I2S comprises greater than about 95% conversion of the cysteine ​​residue corresponding to Cys59 of SEQ ID NO:1 to Cα-formylglycine (FGly). (Item 16) 14. The composition of claim 13, wherein the purified recombinant I2S contains substantially 100% conversion of the cysteine ​​residue corresponding to Cys59 of SEQ ID NO:1 to Cα-formylglycine (FGly). (Item 17) The composition of any one of the preceding items, wherein the purified recombinant I2S has an amino acid sequence at least 80% identical to SEQ ID NO:1. (Item 18) The composition of any one of the preceding items, wherein the purified recombinant I2S has an amino acid sequence that is at least 90% identical to SEQ ID NO:1. (Item 19) The composition of any one of the preceding items, wherein the purified recombinant I2S has an amino acid sequence at least 95% identical to SEQ ID NO:1. (Item 20) The composition of any one of the preceding items, wherein the purified recombinant I2S has an amino acid sequence identical to SEQ ID NO:1. (Item 21) A formulation comprising the composition of any one of the preceding items and a physiologically acceptable carrier. (Item 22) 22. The formulation according to item 21, wherein the formulation is suitable for intravenous administration. (Item 23) 22. The formulation according to item 21, wherein the formulation is suitable for intrathecal administration. (Item 24) 22. The formulation according to item 21, wherein the formulation is suitable for subcutaneous administration. (Item 25) 22. The formulation according to item 21, wherein the formulation is for treating Hunter Syndrome. (Item 26) 1. A method comprising purifying recombinant iduronate-2-sulfatase (I2S) protein from an impure preparation by performing one or more of anion exchange chromatography, cation exchange chromatography, mixed mode chromatography, and hydrophobic interaction chromatography, wherein the method involves fewer than six chromatography steps, and the purified recombinant I2S protein contains less than 100 ng / mg of host cell protein (HCP). (Item 27) 27. The method according to item 26, wherein the anion exchange chromatography is Q chromatography. (Item 28) 28. The method according to item 26 or 27, wherein the cation exchange chromatography is SP chromatography. (Item 29) 29. The method according to any one of items 26 to 28, wherein the mixed mode chromatography is hydroxyapatite (HA) chromatography. (Item 30) 30. The method according to any one of items 26 to 29, wherein the hydrophobic interaction chromatography is phenyl chromatography. (Item 31) 31. The method according to any one of items 26 to 30, wherein the method involves five or fewer chromatography steps. (Item 32) 32. The method according to any one of items 26 to 31, wherein the method involves four or fewer chromatography steps. (Item 33) 33. The method according to any one of items 26 to 32, wherein the method comprises performing anion exchange chromatography, cation exchange chromatography, mixed mode chromatography, and hydrophobic interaction chromatography in this order. (Item 34) 34. The method according to any one of items 26 to 33, wherein upon loading of the impure preparation or intermediate elution, the anion exchange chromatography column is washed with a wash buffer comprising NaCl at a concentration ranging from about 140 mM to 200 mM at pH 5.5. (Item 35) 35. The method according to any one of items 26 to 34, wherein the anion exchange chromatography column is eluted with an elution buffer comprising a linear NaCl gradient. (Item 36) 34. The method according to item 33, wherein the linear NaCl gradient comprises NaCl in the range of 0 to 500 mM. (Item 37) 37. The method according to any one of items 26 to 36, wherein the impure preparation or intermediate eluate is adjusted to a conductivity in the range of about 1 mS / cm to about 20 mS / cm before being loaded onto the column of cation exchange chromatography. (Item 38) 38. The method of claim 37, wherein the cation exchange chromatography column is operated at a pH of about 5.5. (Item 39) 39. The method according to any one of items 26 to 38, wherein the impure preparation or intermediate eluate is adjusted to a phosphate concentration in the range of about 0.001 to 0.01 M and pH 5.5 before being loaded onto the column of the mixed mode chromatography. (Item 40) 40. The method of claim 39, wherein the mixed mode chromatography column, once loaded, is washed with a wash buffer comprising a phosphate concentration in the range of about 10 to 20 mM, pH 5.5. (Item 41) 41. The method according to item 40, wherein the mixed mode chromatography column is eluted with an elution buffer comprising a phosphate concentration in the range of about 50 to 150 mM, pH 5.5. (Item 42) 42. The method according to any one of items 26 to 41, wherein the impure preparation or intermediate eluate is adjusted to a salt concentration in the range of about 0.5 to 2.0 M, a pH of about 4.5 to 6.0 before being loaded onto the column of hydrophobic interaction chromatography. (Item 43) 43. The method according to item 42, wherein the hydrophobic interaction chromatography column, once loaded, is washed with a wash buffer comprising a salt concentration in the range of about 0.5 to 2.0 M, a pH of about 4.5 to 6.0. (Item 44) Item 44. The method according to item 43, wherein the hydrophobic interaction chromatography column is eluted with an elution buffer comprising a salt concentration in the range of about 0.1 to 0.5 M, and a pH of about 4.5 to 6.0. (Item 45) The method according to any one of items 26 to 44, wherein the column height of each of the anion exchange chromatography, the cation exchange chromatography, the mixed mode chromatography, and the hydrophobic interaction chromatography is in the range of 14 to 25 cm. (Item 46) The method according to any one of the preceding items, wherein the method further comprises the step of inactivating the virus. (Item 47) 47. The method according to item 46, wherein a viral inactivation step is carried out prior to loading the impure preparation onto the first chromatography column. (Item 48) 47. The method according to item 46, wherein the step of inactivating the virus comprises adding a detergent to the impure preparation. (Item 49) 49. The method according to any one of items 26 to 48, wherein the method further comprises a step of removing viruses after the last chromatography column. (Item 50) 50. The method according to any one of items 26 to 49, wherein the method further comprises the steps of ultrafiltration and / or diafiltration. (Item 51) 51. The method of claim 50, wherein the ultrafiltration and / or diafiltration step comprises exchanging the recombinant I2S protein into a drug formulation buffer. (Item 52) 52. The method according to any one of items 26 to 51, wherein the recombinant I2S protein has an amino acid sequence that is at least 70% identical to SEQ ID NO:1. (Item 53) 53. The method according to any one of items 26 to 52, wherein the recombinant I2S protein has an amino acid sequence identical to SEQ ID NO:1. (Item 54) 54. The method according to any one of items 26 to 53, wherein the recombinant I2S protein is produced by mammalian cells cultured in suspension in a serum-free medium. (Item 55) 55. The method of item 54, wherein the mammalian cells are cultured in a bioreactor. (Item 56) 56. The method according to item 54 or 55, wherein the serum-free medium is devoid of animal-derived components. (Item 57) 57. The method according to any one of items 54 to 56, wherein the serum-free medium is a chemically defined medium. (Item 58) 57. The method according to any one of items 54 to 56, wherein the mammalian cell co-expresses a recombinant I2S protein and formylglycine synthase (FGE). (Item 59) 59. The method according to item 58, wherein the mammalian cell is a human cell. (Item 60) 60. The method according to any one of items 54 to 59, wherein the impure preparation is prepared from a serum-free medium containing recombinant I2S protein secreted from mammalian cells. (Item 61) 61. The method according to item 60, wherein the impure preparation is lysed from a frozen medium preparation. (Item 62) 62. The method according to any one of items 26 to 61, wherein the purified recombinant I2S protein contains less than 80 ng / mg HCP. (Item 63) 63. The method according to any one of items 26 to 62, wherein the purified recombinant I2S protein contains less than 60 ng / mg HCP. (Item 64) 64. The method according to any one of items 26 to 63, wherein the purified recombinant I2S protein contains, on average, 16 to 22 sialic acids per molecule. (Item 65) 64. The method according to any one of items 26 to 63, wherein the purified recombinant I2S protein has a specific activity of at least 60 U / mg as determined by in vitro sulfate release activity using heparin disaccharide as a substrate. (Item 66) A pharmaceutical composition comprising a recombinant I2S protein purified according to the method according to any one of items 26 to 65. (Item 67) 67. A method for treating Hunter syndrome, comprising administering the pharmaceutical composition according to item 66 to a subject in need of treatment. [Brief description of the drawings]

[0027] The figures described below, taken together, are for illustrative purposes only and are not meant to be limiting. [Figure 1] An exemplary purification scheme for recombinant I2S produced in serum-free medium is described. [Diagram 2] 1 depicts an exemplary peptide map of purified recombinant I2S AF compared to a reference I2S. [Diagram 3] An exemplary SDS-PAGE (silver) analysis of purified recombinant I2S AF is described. [Figure 4] An exemplary charge profile analysis of purified recombinant I2S AF assessed by ion exchange chromatography is described. [Diagram 5] 1 describes an exemplary glycan map profile of purified recombinant I2S AF. [Figure 6] An exemplary activity assay (U / mg) of a clarified harvest of recombinant I2S following a viral inactivation UPB step is described. [Figure 7] An exemplary SEC-HPLC analysis of a clarified harvest of recombinant I2S following a viral inactivation UPB step is described. [Figure 8] 1 depicts an exemplary SDS-PAGE of purified recombinant I2S protein followed by silver staining. [Figure 9] 1 shows an exemplary peptide map for purified recombinant I2S enzyme produced from the I2S-AF 2D cell line grown in serum-free media conditions (top panel) compared to a reference. [Figure 10] The characteristics of exemplary glycans generated on purified recombinant I2S enzymes produced using I2S-AF 2D and 4D cell lines grown in serum-free media conditions are described when compared to a reference. [Figure 11]1 describes exemplary charge profiles generated for purified recombinant I2S enzymes produced using I2S-AF 2D and 4D cell lines grown in serum-free media conditions as compared to an I2S reference control. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0028] definition In order to facilitate a better understanding of the present invention, certain terms are first defined below. Additional definitions for these terms, as well as other terms, are set forth throughout the specification.

[0029] Approximately or about: The term "approximately" or "about" as used herein with respect to one or more values ​​of interest means a value that is approximately the same as the stated reference value. In one embodiment, the term "approximately" or "about" means a range of values ​​that is within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction of the stated reference value (greater or less than), unless otherwise specifically indicated or clearly indicated by the context (except where the number exceeds 100% of the possible values).

[0030] Biologically active: The phrase "biologically active" as used herein refers to any characteristic of a substance that has activity in a biological system (e.g., a cell culture, an organism, etc.). For example, a substance is considered to be biologically active when it is administered to an organism and produces a biological effect in the organism. Biological activity can also be determined by an in vitro assay (e.g., an in vitro enzyme test such as a sulfate release assay). In certain embodiments, if a protein or polypeptide is biologically active, a portion of the protein or polypeptide that shares at least one biological activity of the protein or polypeptide is typically referred to as a "biologically active" portion. In some embodiments, the protein is produced and / or purified from a cell culture system and exhibits biological activity when administered to a subject. In some embodiments, the protein requires further processing to become biologically active. In some embodiments, the protein requires post-translational modifications, such as, but not limited to, glycosylation (e.g., sialylation), farnesylation, cleavage, folding, formylglycine conversion, and combinations thereof, to become biologically active. In some embodiments, proteins produced as proforms (ie, immature forms) may require additional modifications in order to become biologically active.

[0031] Cation-independent mannose 6-phosphate receptor (CI-MPR): The term "cation-independent mannose 6-phosphate receptor (CI-MPR)" as used herein refers to a molecular receptor that binds the mannose 6-phosphate receptor (M6P) tag on acid hydrolase precursors in the Golgi apparatus that are destined for transport to lysosomes. In addition to mannose 6-phosphate, CI-MPR also binds other proteins, including IGF-II. CI-MPR is also known as "M6P / IGF-II receptor", "CI-MPR / IGF-II receptor", "IGF-II receptor", or "IGF2 receptor". These terms and their abbreviations are used interchangeably herein.

[0032] Chromatography: The term "chromatography" as used herein refers to a technique for separating mixtures. Typically, the mixture is dissolved in a liquid called the "mobile phase" and passed through a structure that holds another material called the "stationary phase." Column chromatography refers to a separation technique in which a fixed bed is contained within a tube, or column.

[0033] Diluent: The term "diluent" as used herein means a pharma- ceutically acceptable (e.g., safe and non-toxic for administration to humans) diluent substance useful for preparing a reconstituted formulation. Exemplary diluents include sterile water, bacteriostatic water for injection (BWFI), pH buffered solutions (phosphate buffered saline), sterile saline solution, Ringer's solution, or dextrose solution.

[0034] Elution: The term "elution" as used herein means the process of extracting one substance from another by washing with a solvent. For example, in ion exchange chromatography, elution is the process of washing a loaded resin to remove trapped ions.

[0035] Eluate: The term "eluate" refers to the combination of mobile phase "carrier" and analyte that emerges from chromatography, typically as a result of elution.

[0036] Enzyme replacement therapy (ERT): The term "enzyme replacement therapy (ERT)" as used herein refers to a therapeutic strategy that corrects an enzyme deficiency by providing the missing enzyme. Once administered, the enzyme is taken up by the cell and transported to the lysosome, where it acts to remove material that has accumulated in the lysosome due to the enzyme deficiency. Typically, lysosomal enzyme replacement therapy is effective, where the therapeutic enzyme is delivered to the appropriate intracellular lysosomes of the target cell where the storage defect appears.

[0037] Equilibrate or equilibration: The term "equilibrate" or "equilibration," as used herein in reference to chromatography, refers to the process of balancing a first liquid (e.g., a buffer) with another, usually to achieve a stable and even distribution of the components of the liquid (e.g., a buffer). For example, in some embodiments, a chromatography column may be equilibrated by passing one or more column volumes of a desired liquid (e.g., a buffer) through the column.

[0038] Improve, Increase or Decrease: The terms "improve," "increase," or "decrease," or grammatical equivalents, as used herein, refer to a value that is relative to a baseline measurement, such as a measurement of the same individual prior to beginning a treatment as described herein, or a measurement of a control individual (or control individuals) not receiving a treatment as described herein. A "control individual" is an individual who suffers from the same form of lysosomal storage disease as the individual receiving the treatment, and who is approximately the same age as the individual receiving the treatment (so as to ensure comparison of the stage of disease in treated and control individuals).

[0039] Impurity: The term "impurity" as used herein means a substance in a limited amount of a liquid, gas, or solid that is distinct from the chemical composition of the target substance or compound. Impurities are also referred to as contaminants.

[0040] Linker: The term "linker" as used herein means an amino acid sequence in the fusion protein that does not occur at a specific position in the natural protein, and is usually designed to be flexible or to insert into a structure such as an alpha helix between two protein moieties. Linker is also referred to as spacer.

[0041] Load: The term "load" as used herein means adding a liquid or solid containing a sample to a column during chromatography. In some embodiments, certain components of the sample loaded onto the column are captured as the loaded sample and pass through the column. In some embodiments, certain components of the sample loaded onto the column are not captured by the column or "pass through" and the column as the loaded sample passes through the column.

[0042] Polypeptide: The term "polypeptide," as it is commonly referred to, is a string of at least two amino acids linked together by peptide bonds. In some embodiments, a polypeptide may contain at least 3-5 amino acids, each of which is linked to the others by at least one peptide bond. One of skill in the art will understand that a polypeptide may contain "unnatural" amino acids or other entities that may otherwise be incorporated into a polypeptide chain.

[0043] Pooling: The term "pooling," as used herein in reference to chromatography, means combining one or more fractions of a liquid that have passed through a column together. For example, in some embodiments, one or more fractions (e.g., "peak fractions") that contain desired components of a sample separated by chromatography can be "pooled" together to produce a single "pooled" fraction.

[0044] Replacement enzyme: The term "replacement enzyme" as used herein refers to an enzyme that can act to at least partially replace an enzyme that is deficient or lost in a disease being treated. In some embodiments, the term "replacement enzyme" refers to an enzyme that can act to at least partially replace an enzyme that is deficient or lost in a lysosomal storage disease being treated. In some embodiments, the replacement enzyme can reduce substances stored in mammalian lysosomes or rescue or ameliorate one or more symptoms of a lysosomal storage disease. Replacement enzymes suitable for the present invention include both wild-type or modified lysosomal enzymes and can be produced using recombinant and synthetic methods or purified from natural sources. Replacement enzymes can be recombinant, synthetic, genetically active or natural enzymes.

[0045] Soluble: The term "soluble" as used herein refers to the ability of a therapeutic agent to form a homogeneous solution. In some embodiments, the solubility of the therapeutic agent in solution is sufficient to allow the therapeutic agent to be administered and thereby transported to the target site of activity to deliver a therapeutically effective amount of the therapeutic agent to the target site of activity. Several factors may affect the solubility of a therapeutic agent. For example, relevant factors that may affect the solubility of a protein include ionic strength, amino acid sequence, and the presence of other co-soluble agents or salts (e.g., calcium salts). In some embodiments, the therapeutic agent described in the present invention is soluble in the corresponding pharmaceutical composition.

[0046] Stability: The term "stable" as used herein refers to the ability of a therapeutic agent (e.g., a recombinant enzyme) to maintain therapeutic efficacy (e.g., all or most of the intended biological activity and / or physiochemical integrity) over an extended period of time. The stability of a therapeutic agent and the ability of a pharmaceutical composition to maintain the stability of said therapeutic agent may be evaluated over an extended period of time (e.g., for at least 1, 3, 6, 12, 18, 24, 30, 36 months or more). In the context of a formulation, a stable formulation is one in which the therapeutic agent essentially retains its physical and / or chemical integrity and biological activity during storage and processing (such as freezing / thawing, mechanical mixing and lyophilization). Protein stability can be measured by the formation of high molecular weight (HMW) aggregates, loss of enzymatic activity, generation of peptide fragments and changes in charge characteristics.

[0047] Virus processing: The term "virus processing" as used herein means "virus removal" where the virus is simply removed from the sample, or "virus inactivation" where the virus is present in the sample but in a non-infectious form. In some embodiments, virus removal may use nanofiltration and / or chromatographic techniques, among others. In some embodiments, virus inactivation may use solvent inactivation, detergent inactivation, pasteurization, acidic pH inactivation, and / or ultraviolet inactivation, among others.

[0048] Detailed Description of the Invention The present invention provides, inter alia, an improved method of purifying recombinant I2S protein for enzyme replacement therapy based on a process comprising less than six chromatography steps. In some embodiments, the present invention provides a method of purifying recombinant I2S protein from an impure preparation using a process based on one or more of anion exchange chromatography, cation exchange chromatography, mixed mode chromatography, and hydrophobic interaction chromatography. In some embodiments, the present invention provides a method of purifying recombinant I2S protein from an impure preparation by performing Q chromatography, hydroxyapatite (HA) chromatography, SP chromatography, and phenyl chromatography. The present invention further provides purified recombinant I2S protein and uses thereof.

[0049] The following subsections describe various aspects of the invention in further detail. The use of the subsections is not intended to limit the invention. Each subsection may apply to any aspect of the invention. In this application, the use of "or" means "and / or" unless otherwise stated.

[0050] Recombinant I2S protein As used herein, an I2S protein is a protein or portion of a protein that can replace at least partial activity of a naturally occurring iduronate-2-sulfatase (I2S) protein or can rescue one or more phenotypes or symptoms associated with an I2S deficiency. As used herein, the terms "I2S enzyme" and "I2S protein" and grammatical equivalents are used interchangeably.

[0051] Typically, the human I2S protein is produced as a precursor form. The precursor form of human I2S contains a signal peptide (amino acid residues 1-25 of the full-length precursor), a propeptide (amino acid residues 26-33 of the full-length precursor), a chain (residues 34-550 of the full-length precursor) that can be further processed to a 42 kDa chain (residues 34-455 of the full-length precursor), and a 14 kDa chain (residues 446-550 of the full-length precursor). Typically, the precursor form is also referred to as the full-length precursor or full-length I2S protein, which contains 550 amino acids. The amino acid sequences of the mature form (SEQ ID NO: 1) and the full-length precursor (SEQ ID NO: 2) of the typically wild-type or naturally occurring human I2S protein, with the signal peptide removed, are shown in Table 1. The signal peptide is underlined. Additionally, the amino acid sequences of the precursors of human I2S protein isoforms a and b are also provided in Table 1 as SEQ ID NOs: 3 and 4, respectively.

[0052] [Table 1-1] [Table 1-2]

[0053] Thus, in some embodiments, the recombinant I2S protein is the human mature I2S protein (SEQ ID NO: 1). As disclosed herein, SEQ ID NO: 1 represents the standard amino acid sequence of the human I2S protein. In some embodiments, the I2S protein may be a splice isoform and / or variant of SEQ ID NO: 1 resulting from transcription at an alternative start site within the 5'UTR of the I2S gene. In some embodiments, a suitable recombinant I2S protein may be a homolog or analog of the human mature I2S protein. For example, a homolog or analog of the human mature I2S protein may be a modified human mature I2S protein that contains one or more amino acid substitutions, deletions and / or insertions compared to the wild-type or naturally occurring I2S protein (e.g., SEQ ID NO: 1) but retains substantial I2S protein activity. Thus, in some embodiments, the recombinant I2S protein is substantially homologous to the human mature I2S protein (SEQ ID NO: 1). In some embodiments, the recombinant I2S protein has an amino acid sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NO: 1. In some embodiments, the recombinant I2S protein is substantially identical to the mature human I2S protein (SEQ ID NO: 1). In some embodiments, the recombinant I2S protein has an amino acid sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NO: 1. In some embodiments, the recombinant I2S protein contains a fragment or portion of the mature human I2S protein.

[0054] Alternatively, the recombinant I2S protein is a full-length I2S protein. In some embodiments, the recombinant I2S protein may be a homolog or analog of the full-length human I2S protein. For example, a homolog or analog of the full-length human I2S protein may be a modified full-length human I2S protein that contains one or more amino acid substitutions, deletions, and / or insertions compared to a wild-type or naturally occurring full-length I2S protein, but retains substantial I2S protein activity. Thus, in some embodiments, the recombinant I2S protein is substantially homologous to the full-length human I2S protein (SEQ ID NO:2). For example, the recombinant I2S protein has an amino acid sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more homologous to SEQ ID NO:2. In some embodiments, the recombinant I2S protein is substantially identical to SEQ ID NO:2. For example, the recombinant I2S protein has an amino acid sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NO:2. In some embodiments, the recombinant I2S protein contains a fragment or portion of a full-length human I2S protein. As used herein, a full-length I2S protein typically contains a signal peptide sequence.

[0055] In some embodiments, the recombinant I2S protein is a human I2S isoform a protein. In some embodiments, the recombinant I2S protein may be a homolog or analog of a human I2S isoform a protein. For example, a homolog or analog of a human I2S isoform a protein may be a modified human I2S isoform a protein that contains one or more amino acid substitutions, deletions, and / or insertions compared to a wild-type or naturally occurring human I2S isoform a protein (e.g., SEQ ID NO:3), but retains substantial I2S protein activity. Thus, in some embodiments, the recombinant I2S protein is substantially homologous to a human I2S isoform a protein (SEQ ID NO:3). For example, the recombinant I2S protein has an amino acid sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more homologous to SEQ ID NO:3. In some embodiments, the recombinant I2S protein is substantially identical to SEQ ID NO:3. For example, the recombinant I2S protein has an amino acid sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NO:3. In some embodiments, the recombinant I2S protein contains a fragment or portion of a human I2S isoform a protein. As used herein, a human I2S isoform a protein typically contains a signal peptide sequence.

[0056] In some embodiments, the recombinant I2S protein is a human I2S isoform b protein. In some embodiments, the recombinant I2S protein may be a homolog or analog of a human I2S isoform b protein. For example, a homolog or analog of a human I2S isoform b protein may be a modified human I2S isoform b protein that contains one or more amino acid substitutions, deletions, and / or insertions compared to a wild-type or naturally occurring human I2S isoform b protein (e.g., SEQ ID NO: 4), but retains substantial I2S protein activity. Thus, in some embodiments, the recombinant I2S protein is substantially homologous to a human I2S isoform b protein (SEQ ID NO: 4). For example, the recombinant I2S protein has an amino acid sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more homologous to SEQ ID NO: 4. In some embodiments, the recombinant I2S protein is substantially identical to SEQ ID NO: 4. For example, the recombinant I2S protein has an amino acid sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NO: 4. In some embodiments, the recombinant I2S protein contains a fragment or portion of a human I2S isoform b protein. As used herein, a human I2S isoform b protein typically contains a signal peptide sequence.

[0057] Homologs or analogs of the human I2S protein can be prepared according to methods of altering polypeptide sequences known to those of skill in the art, as found in the literature accumulating such methods. In some embodiments, conservative amino acid substitutions include substitutions made between amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D. In some embodiments, a "conservative amino acid substitution" refers to an amino acid substitution that does not alter the relative charge or size characteristics of the protein in which the amino acid substitution is made.

[0058] In some embodiments, the recombinant I2S protein may contain a moiety that binds to a receptor on the surface of a target cell to facilitate cellular uptake and / or lysosomal targeting. For example, such a receptor may be the cation-dependent mannose-6-phosphate receptor (CI-MPR), which binds mannose-6-phosphate (M6P) residues. In addition, the CI-MPR also binds other proteins, including IGF-II. In some embodiments, the recombinant I2S protein contains M6P residues on the surface of the protein. Specifically, the recombinant I2S protein may contain bisphosphorylated oligosaccharides that have a higher binding affinity to the CI-MPR. In some embodiments, a suitable enzyme contains up to, approximately, an average of at least about 20% bisphosphorylated oligosaccharides per enzyme. In other embodiments, a suitable enzyme may contain about 10%, 15%, 18%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60% bisphosphorylated oligosaccharides per enzyme.

[0059] In some embodiments, the recombinant I2S enzyme may be fused to a lysosomal targeting moiety capable of binding to a receptor on the surface of a target cell. Suitable lysosomal targeting moieties may be IGF-I, IGF-II, RAP, p97, and variants, homologs, or fragments thereof (e.g., including those peptides having a sequence that is at least 70%, 75%, 80%, 85%, 90% or 95% identical to the human wild-type mature IGF-I, IGF-II, RAP, p97 peptide sequence). The lysosomal targeting moiety may be linked or fused to the I2S protein or enzyme at the N-terminus, C-terminus, or internally.

[0060] Production of recombinant I2S protein The present invention may be used to purify recombinant I2S protein produced in a variety of ways. For example, I2S protein may be produced recombinantly by using a host cell line engineered to express a nucleic acid encoding I2S. Alternatively, I2S protein may be produced by activating an endogenous I2S gene.

[0061] It will be appreciated that the present invention may be used to purify recombinant I2S proteins produced using a variety of expression systems, including, for example, egg, baculovirus, plant, yeast, or mammalian cells.

[0062] In some embodiments, the I2S enzyme is produced in a mammalian cell. Non-limiting examples of mammalian cells that may be used in accordance with the present invention include BALB / c mouse myeloma line (NSO / 1, ECACC No: 85110503); human retinoblastoma cells (PER.C6, CruCell, Leiden, The Netherlands); monkey kidney CV1 line transfected with SV40 (COS-7, ATCC CRL 1651); human embryonic kidney lines (HEK293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen Virol., 36:59, 1977); human fibrosarcoma cell lines (e.g., HT1080); baby hamster kidney cells (BHK21, ATCC CCL 10); Chinese hamster ovary cells + / -DHFR (CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77:4216, 1980); Mouse Sertoli cells (TM4, Mather, Biol. Reprod., 23:243-251, 1980); Cultured monkey kidney cells (CV1 ATCC CCL 70); Cultured African green monkey kidney cells (VERO-76, ATCC CRL-1) 587); human cervical cancer cells (HeLa, ATCC CCL 2); dog kidney cells (MDCK, ATCC CCL 34); buffalo rat hepatocytes (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary cancer (MMT 060562, ATCC) CCL51); TRI cells (Mather et al., Annals NY Acad. Sci., 383:44-68, 1982); MRC5 cells; FS4 cells; and a human hepatoma line (Hep G2).

[0063] In some embodiments, the inventive methods described herein are used to purify recombinant I2S enzymes produced from human cells (e.g., HT1080). In some embodiments, the inventive methods described herein are used to purify recombinant I2S enzymes produced from CHO cells.

[0064] Typically, cells engineered to express recombinant I2S may contain a transgene encoding a recombinant I2S protein as described herein. The nucleic acid encoding recombinant I2S may include regulatory sequences, gene control sequences, promoters, non-coding sequences and / or other suitable sequences for expressing recombinant I2S. Typically, the coding region is operably linked to one or more of these nucleic acid components.

[0065] "Control sequence" refers to a nucleotide sequence that is typically located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence and that influences the transcription, RNA processing or stability, or translation of the associated coding sequence. Control sequences include promoters, translation leader sequences, introns, and polyadenylation recognition sequences. "Control sequence" may also be referred to as "gene control sequence."

[0066] A "promoter" typically refers to a nucleotide sequence capable of controlling the expression of a coding sequence or functional RNA. Usually, the coding sequence is located at the 3 position of the promoter sequence. A promoter sequence consists of proximal and distal upstream elements, the latter elements often referred to as enhancers. Thus, an "enhancer" is a nucleotide sequence capable of stimulating promoter activity, and may be an element of the native promoter or a heterologous element inserted to increase the level or tissue specificity of the promoter. A promoter may be entirely derived from a wild-type gene, or may be composed of different elements derived from different promoters found in nature, or may contain synthetic nucleotide fragments. Those skilled in the art will appreciate that different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of expression, or in response to different environmental conditions.

[0067] "3' non-coding sequences" refers to nucleotide sequences that are typically located downstream of a coding sequence and include polyadenylation recognition sequences and other sequences that encode regulatory signals that can affect mRNA processing or gene expression. Polyadenylation signals are often characterized as affecting the addition of polyadenylic acid to the 3' end of a pre-mRNA.

[0068] "Translation leader sequence" or "5' non-translated sequence" refers to a nucleotide sequence that is typically located between the promoter sequence and the coding sequence of a gene. Translation leader sequences are present in the fully processed mRNA upstream of the translation start sequence. Translation leader sequences can affect the processing of the primary transcript on the mRNA, mRNA stability, or translation efficiency.

[0069] Typically, the term "operably linked" refers to the association of two or more nucleic acid fragments on a single nucleic acid fragment such that the function of one is affected by the other. For example, a promoter is operably linked to a coding sequence when it can affect the expression of the coding sequence (i.e., the coding sequence is under the transcriptional control of the promoter). The coding sequence can be operably linked to a control sequence in a sense or antisense orientation.

[0070] The coding region of the transgene may contain one or more silent mutations to optimize codon usage for a particular cell type. For example, the codons of the I2S transgene may be optimized for expression in vertebrate cells. In some embodiments, the codons of the I2S transgene may be optimized for expression in mammalian cells. In some embodiments, the codons of the I2S transgene may be optimized for expression in human cells.

[0071] The construct may contain one or more of the following additional components: splice sites, enhancer sequences, a selectable marker gene under a suitable promoter, an amplifiable marker gene under a suitable promoter, and matrix attachment regions (MARs) or other elements known to those of skill in the art that enhance expression of the inserted region.

[0072] Once transfected or transduced into a host cell, suitable vectors can be expressed extrachromosomally (episomal) or integrated into the host cell genome.

[0073] Activation of recombinant I2S protein Typically, recombinant I2S enzymes are activated by post-translationally modifying a conserved cysteine ​​(corresponding to amino acid 59 of mature human I2S) to formylglycine, also known as 2-amino-3-oxopropionic acid or oxo-alanine. Such post-translational modification can be performed by an enzyme known as formylglycine generating enzyme (FGE). Thus, in some embodiments, recombinant I2S enzymes are produced in cells that also express FGE protein. In certain embodiments, recombinant I2S enzymes are produced in cells that increase or enhance expression of FGE protein. For example, cells may be engineered to overexpress FGE in combination with recombinant I2S to facilitate producing preparations of I2S with high levels of active enzyme. In some embodiments, overexpression of FGE is achieved by expressing (e.g., overexpressing) exogenous FGE using standard recombinant techniques. In some embodiments, overexpression of FGE is achieved by activating or enhancing expression of exogenous FGE, for example, by activating or enhancing the promoter of the exogenous FGE gene. In some cases, for example, the nucleic acid encoding the recombinant I2S and the nucleic acid encoding the recombinant FGE protein are linked by a nucleic acid having a sequence corresponding to an internal ribosome entry region (e.g., a spacer sequence).

[0074] FGE having the ability to convert cysteine ​​to formylglycine may be used in the present invention. Exemplary nucleic acid and amino acid sequences for FGE proteins are disclosed in US 2004-0229250, the entire contents of which relating to the sequences and the sequences themselves are incorporated herein by reference in their entirety. A nucleic acid encoding a recombinant FGE may include regulatory sequences, gene control sequences, promoters, non-coding sequences and / or other suitable sequences for expressing FGE. Typically, the coding region is operably linked to one or more of these nucleic acid components.

[0075] Cell culture media and conditions A variety of cell culture media and conditions may be used to produce recombinant I2S protein. For example, recombinant I2S protein may be produced in serum-containing or serum-free media. In some embodiments, recombinant I2S protein may be produced in serum-free media. In some embodiments, recombinant I2S protein may be produced in animal component-free media, i.e., media lacking animal-derived components. In some embodiments, recombinant I2S protein may be produced in chemically defined media. As used herein, the term "chemically defined media" refers to media in which substantially all of the chemical components are known. In some embodiments, chemically defined media are free of, for example, serum, serum-derived proteins (e.g., albumin or fetuin), and other components. In some cases, chemically defined media contain one or more proteins (e.g., protein growth factors or cytokines). In some cases, chemically defined media contain one or more protein hydrolysates. In other cases, chemically defined media are protein-free media, i.e., serum-free media that do not contain proteins, hydrolysates, or components of unknown composition.

[0076] In some embodiments, the chemically defined medium may be supplemented with one or more animal derived components, including, but not limited to, fetal bovine serum, horse serum, goat serum, donkey serum, human serum, and serum derived proteins such as albumin (e.g., bovine serum albumin or human serum albumin).

[0077] A variety of cell culture conditions can be used to produce recombinant I2S protein on a large scale, including, but not limited to, roller bottle culture, bioreactor batch culture, and bioreactor fed-batch culture. In some embodiments, recombinant I2S protein is produced by cells cultured in suspension. In some embodiments, recombinant I2S protein is produced by adherent cells.

[0078] Exemplary cell culture media and culture conditions are described in the Examples section. Additional exemplary methods and compositions for producing recombinant I2S proteins are described in co-filed provisional patent application entitled "Methods and Compositions for Producing Recombinant Iduronate-2-Sulfatase," the disclosure of which is incorporated herein by reference in its entirety.

[0079] Purification of recombinant I2S protein In some embodiments, the present invention provides a method for purifying recombinant I2S protein from an impure preparation using a process based on one or more of anion exchange chromatography, cation exchange chromatography, mixed mode chromatography, and hydrophobic interaction chromatography. In some embodiments, the inventive method described in the present invention involves fewer than six (e.g., fewer than five, fewer than four, or fewer than three) chromatography steps. In some embodiments, the inventive method described in the present invention involves two, three, four, or five chromatography steps. In some embodiments, the inventive method described in the present invention involves four chromatography steps. In some embodiments, the inventive method described in the present invention performs anion exchange chromatography, mixed mode chromatography, cation exchange chromatography, and hydrophobic interaction chromatography in this order.

[0080] impure preparations An impure preparation, as used herein, may be biological material, including unprocessed biological material containing recombinant I2S protein. For example, an impure preparation may be raw cell culture medium containing recombinant I2S protein secreted from cells (e.g., mammalian cells) that produce I2S protein, or raw cell lysate containing I2S protein. In some embodiments, an impure preparation may be, in part, raw cell culture medium or cell lysate. For example, the cell culture medium or cell lysate may be concentrated, diluted, and processed for virus inactivation, virus processing, or virus removal. In some embodiments, virus removal may use nanofiltration and / or chromatographic techniques, among others. In some embodiments, virus inactivation may use solvent inactivation, detergent inactivation, pasteurization, acidic pH inactivation, and / or UV inactivation, among others. The cell culture medium or cell lysate may be treated with proteases, DNases, and / or RNases to reduce the levels of host cell proteins and / or nucleic acids (e.g., DNA or RNA). In some embodiments, unprocessed or partially processed biological material (e.g., cell culture media or cell lysates) may be frozen, stored, and thawed for purification at a desired temperature (e.g., 2-8° C., −4° C., −25° C., −75° C.) for a desired period of time. As used herein, impure preparations may also refer to starting material or loading material.

[0081] Anion exchange chromatography In some embodiments, the provided method for purifying recombinant I2S includes anion exchange chromatography. Briefly, anion exchange chromatography is a chromatographic technique that relies on charge-charge interactions between a negatively charged compound and a positively charged resin. In some embodiments, the anion exchange chromatography is strong anion exchange chromatography. In some embodiments, anion exchange chromatography is used as the first purification step of a therapeutic protein (e.g., recombinant I2S).

[0082] Exemplary anion exchange resins include, but are not limited to, quaternary amine resins or "Q resins" (e.g., Capto™-Q, Q-Sepharose®, QAE Sephadex®); diethylaminoethane (DEAE) resins (e.g., DEAE-Trisacryl®, DEAE Sepharose®, benzoylated naphthoylated DEAE, diethylaminoethyl Sephacel®); Amberjet® resins; Amberlyst® resins; Amberlite® resins (e.g., Amberlite® IRA-67, Amberlite® strong base, Amberlite® weak base), cholestyramine resins, ProPac® resins (e.g., ProPac® SAX-10, ProPac® WAX-10, ProPac® WCX-10); TSK-GEL® resins (e.g., TSKgel® 10, ProPac ... DEAE-NPR; TSKgel DEAE-5PW); and Acclaim® resin. In certain embodiments, the anion exchange resin is Q resin.

[0083] Typical mobile phases for anion exchange chromatography include water, acetonitrile, organic alcohols such as methanol, ethanol, and isopropanol, or relatively polar solutions such as solutions containing 2-(N-morpholino)-ethanesulfonic acid (MES). Thus, in certain embodiments, the mobile phase includes about 0%, 1%, 2%, 4%, 6%, 8%, 10%, 12%, 14%, 16%, 18%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or about 100% of a polar solution. In certain embodiments, the mobile phase comprises between about 1% and about 100%, about 5% and about 95%, about 10% and about 90%, about 20% and about 80%, about 30% and about 70%, or about 40% and about 60% of a polar solution at any given time during the separation.

[0084] Typically, the mobile phase comprises a salt. For example, a salt (e.g., sodium chloride) can elute bound proteins from an anion exchange column (e.g., the counterion is chloride, which is exchanged for the target protein and then released). In some embodiments, the mobile phase comprises a salt concentration of about 0 to about 1.0 M, e.g., about 0 to about 0.8 M, about 0 to about 0.6 M, about 0 to about 0.5 M, about 0 to about 0.4 M, about 0.05 M to about 0.50 M, about 0.10 M to about 0.45 M, about 0.10 M to about 0.40 M, or about 0.15 M to about 0.40 M. In some embodiments, the mobile phase comprises a salt concentration of about 0.01M, 0.02M, 0.03M, 0.04M, 0.05M, 0.06M, 0.07M, 0.08M, 0.09M, 0.1M, 0.2M, 0.3M, 0.4M, 0.5M, 0.6M, 0.7M, 0.8M, 0.9M, or 1.0M. In some embodiments, the salt concentration of the mobile phase is gradient (e.g., linear or non-linear gradient). In some embodiments, the salt concentration of the mobile phase is constant. In some embodiments, the salt concentration of the mobile phase may be increased or decreased in steps.

[0085] Typically, the mobile phase is buffered. In certain embodiments, the mobile phase is unbuffered. In certain embodiments, the mobile phase is buffered at a pH of about 5 to about 14. In certain embodiments, the mobile phase is buffered at a pH of about 5 to about 10. In certain embodiments, the mobile phase is buffered at a pH of about 5 to about 7. In certain embodiments, the mobile phase is buffered at a pH of about 6.5. In certain embodiments, the mobile phase is buffered at a pH of about 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10.

[0086] In some embodiments, the impure preparation or intermediate eluate or flow through is adjusted to a pH of about 5.0, 5.5, 6.0, 6.5, 7.0 or 7.5 and a conductivity of about 2 mS / cm, 4 mS / cm, 6 mS / cm, 8 mS / cm, 10 mS / cm, 12 mS / cm, 14 mS / cm, 16 mS / cm, 18 mS / cm, or 20 mS / cm prior to loading onto an anion exchange chromatography column (e.g., a Q column). The pH is adjusted using sodium acetate (e.g., 1 M) and the conductivity is adjusted using sodium chloride (e.g., 5 M). Once loaded, the anion exchange chromatography column may be washed using a wash buffer comprising a salt (e.g., NaCl) concentration ranging from about 140 mM to about 200 mM (e.g., about 140 mM, 145 mM, 150 mM, 155 mM, 160 mM, 165 mM, 170 mM, 175 mM, 180 mM, 185 mM, 190 mM, 195 mM, or 200 mM), a pH of about 5.0 to 7.5 (e.g., about 5.0, 5.5, 6.0, 6.5, 7.0, or 7.5). The anion exchange chromatography column may be eluted using an elution buffer comprising a linear NaCl gradient. Suitable exemplary linear NaCl gradients can include a range of about 0-500 mM NaCl (e.g., about 0-400 mM, about 0-350 mM, about 0-300 mM, about 50-500 mM, about 150-500 mM, about 150-450 mM, about 150-400 mM).

[0087] Cation exchange chromatography In some embodiments, the method provided for purifying recombinant I2S includes cation exchange chromatography.Simply put, cation exchange chromatography is a chromatographic technique that relies on charge-charge interaction between positively charged compounds and negatively charged resin.In some embodiments, cation exchange chromatography is strong cation exchange chromatography.

[0088] Cation exchange chromatography is typically performed on either strong or weak cation exchange columns, containing sulfonium ions or weak cation exchangers that typically contain carboxymethyl (CM) or carboxylate (CX) functional groups. Many suitable cation exchange resins are well known in the art and commercially available, including, but not limited to, SP-Sepharose®, CM Sepharose®; Am berjet® resin; Amberlyst® resin; Amberlite® resin (e.g., Amberlite® IRA120); ProPac® resin (e.g., ProPac® SCX-10, ProPac® WCX-10, ProPac® WCX-10); TSK-GEL® resin (e.g., TSKgel BioAssist S; TSKgel SP-2SW, TSKgel SP-5PW; TSKgel SP-NPR; TSKgel SCX; TSKgel SP-STAT; TSKgel CM-5PW; TSKgel OApak-A; TSKgel CM-2SW, TSKgel CM-3SW, and TSKgel CM-STAT); and Acclaim® resin. In an embodiment, the anion exchange resin is SP-Sepharose resin.

[0089] Typical mobile phases for cation exchange chromatography include water, acetonitrile, organic alcohols such as methanol, ethanol, and isopropanol, or relatively polar solutions such as solutions containing 2-(N-morpholino)-ethanesulfonic acid (MES). Thus, in certain embodiments, the mobile phase comprises about 0%, 1%, 2%, 4%, 6%, 8%, 10%, 12%, 14%, 16%, 18%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or about 100% of a polar solution. In certain embodiments, the mobile phase comprises from about 1% to about 100%, from about 5% to about 95%, from about 10% to about 90%, from about 20% to about 80%, from about 30% to about 70%, or from about 40% to about 60% of the polar solution at any given time during the separation.

[0090] Typically, the mobile phase comprises a salt. For example, a salt (e.g., sodium chloride, sodium phosphate, etc.) can elute bound proteins from a cation exchange column (e.g., the counterion is sodium, which is exchanged for the target protein and then released). In some embodiments, the mobile phase comprises a salt at a concentration ranging from about 0 to about 1.0 M, e.g., from about 0 to about 0.8 M, from about 0 to about 0.6 M, from about 0 to about 0.5 M, from about 0 to about 0.4 M, from about 0.05 M to about 0.50 M, from about 0.10 M to about 0.45 M, from about 0.10 M to about 0.40 M, or from about 0.15 M to about 0.40 M. In some embodiments, the mobile phase comprises a salt concentration of about 0.01M, 0.02M, 0.03M, 0.04M, 0.05M, 0.06M, 0.07M, 0.08M, 0.09M, 0.1M, 0.2M, 0.3M, 0.4M, 0.5M, 0.6M, 0.7M, 0.8M, 0.9M, or 1.0M. In some embodiments, the salt concentration of the mobile phase is a gradient (e.g., a linear gradient or a non-linear gradient). In some embodiments, the salt concentration of the mobile phase is constant. In some embodiments, the salt concentration of the mobile phase may be increased or decreased stepwise.

[0091] Typically the mobile phase is buffered. In certain embodiments, the mobile phase is unbuffered. In certain embodiments, the mobile phase is buffered to a pH of about 5 to about 14. In certain embodiments, the mobile phase is buffered to a pH of about 5 to about 10. In certain embodiments, the mobile phase is buffered to a pH of about 5 to about 7. In certain embodiments, the mobile phase is buffered to a pH of about 6.5. In certain embodiments, the mobile phase is buffered to a pH of about 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10.

[0092] In some embodiments, the impure preparation or intermediate eluate or flow-through fraction is adjusted to a conductivity in the range of about 1 mS / cm to 20 mS / cm (e.g., about 1 mS / cm to 15 mS / cm, about 1 mS / cm to 10 mS / cm, about 1 mS / cm to 8 mS / cm, about 1 mS / cm to 6 mS / cm, about 1 mS / cm to 4 mS / cm, about 2 mS / cm to 4 mS / cm) before being loaded onto a cation exchange chromatography column (SP column). In certain embodiments, the impure preparation or intermediate eluate or flow-through fraction is adjusted to a conductivity in the range of about 2 mS / cm to 4 mS / cm (e.g., 2, 2.5, 3, 3.5, or 4 mS / cm) before being loaded onto a cation exchange chromatography column (SP column). The conductivity is adjusted by diluting the impure preparation or intermediate eluate or flow-through with HO, for example, in a ratio of 1:1, 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 2.0:1, 2.5:1, 3.0:1, 4.0:1, 5.0:1, or 10:1. The conductivity may also be adjusted by diafiltration into a desired buffer. In some embodiments, the cation exchange chromatography column is operated at a pH of about 5.0 to 6.5 (e.g., about 5.0, 5.5, 6.0, or 6.5). In some embodiments, the cation exchange chromatography column is operated with a buffer containing phosphate (e.g., NaPO4) at a concentration ranging from about 0.01 M to about 0.1 M (e.g., about 0.01 M, 0.02 M, 0.03 M, 0.04 M, 0.05 M, 0.06 M, 0.07 M, 0.08 M, 0.09 M, or 0.1 M). In some embodiments, a suitable pH is about 5.0 to 6.5 (e.g., about 5.0, 5.5, 6.0, or 6.5).

[0093] Mixed-mode chromatography Hydroxyapatite chromatography (HA) is considered to be "pseudo-affinity" chromatography or "mixed-mode" ion exchange and may be used in accordance with the present invention. Hydroxyapatite is a unique form of calcium phosphate used in the fractionation and purification of biomolecules. In some cases, crystalline hydroxyapatite may be used, although the fragility of the crystals may limit flow rates and / or column life. Two types of chemically pure ceramic hydroxyapatites, CHT ceramic hydroxyapatites type I and type II, are macroporous, spherical, and can be used at high flow rates and high pressures. Type I typically has a high protein binding capacity, and type II typically has a low binding capacity for proteins. The formula for hydroxyapatite is usually Ca 10 (PO4)6(OH)2 (Kawasaki et al., 1985). The functional groups contain clusters of six negatively charged oxygen atoms bound to positively charged pairs of crystalline calcium ions (C-sites) and triads of crystalline phosphate (P-sites). The C-sites, P-sites and hydroxyls are distributed in a fixed pattern on the crystal surface and usually result in complex interactions with proteins and other molecules.

[0094] The sample may be loaded onto the HA column in a low ionic strength phosphate buffer (e.g., 1-10 mM sodium or potassium phosphate) at neutral or near-neutral pH. In some embodiments, the impure preparation or intermediate eluate or flow-through is adjusted to a phosphate (e.g., NaPO4) concentration in the range of about 0.001M to about 0.01M (e.g., about 0.001M, 0.002M, 0.003M, 0.004M, 0.005M, 0.006M, 0.007M, 0.008M, 0.009M, or 0.01M) and a pH of about 5.0-6.5 (e.g., about 5.0, 5.5, 6.0, or 6.5) prior to loading onto the mixed-mode chromatography column (e.g., HA column). The loaded HA column is typically washed with a wash buffer having a phosphate concentration comparable to that of the loading buffer. In some embodiments, the mixed-mode chromatography column (e.g., HA column), once loaded, is washed with a wash buffer containing phosphate (e.g., 1-10 mM sodium or potassium phosphate) at neutral or near-neutral pH. For example, a suitable wash buffer may have a phosphate concentration of about 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, or 10 mM. In some embodiments, it is desirable to increase the amount of phosphate in the wash buffer to create more stringent wash conditions. M6P levels, especially di-M6P levels, on the surface of I2S proteins are important for lysosomal targeting. The increased phosphate concentration in the wash buffer selectively retains I2S proteins with high levels of M6P, especially di-M6P on HA columns. Thus, in some embodiments, a desirable wash buffer may have a phosphate concentration of greater than 10 mM, 11 mM, 12 mM, 13 mM, 14 mM, 15 mM, 16 mM, 17 mM, 18 mM, 19 mM, 20 mM, etc. In some embodiments, a loaded mixed-mode chromatography column (e.g., an HA column) is washed with a wash buffer having a phosphate concentration in the range of about 10-20 mM (e.g., about 10-18 mM, 10-16 mM, 10-15 mM, 12-20 mM, 14-18 mM, 14-16 mM).In some embodiments, a loaded mixed-mode chromatography column (e.g., an HA column) is washed with a wash buffer having a phosphate concentration of greater than 10 mM, 11 mM, 12 mM, 13 mM, 14 mM, 15 mM, 16 mM, 17 mM, 18 mM, 19 mM, or 20 mM.

[0095] Elution from the HA column is typically accomplished with a gradient phosphate buffer. For example, a suitable elution buffer may have a gradient of sodium phosphate of about 1-400 mM (e.g., 1-300 mM, 1-200 mM, 1-150 mM, 1-100 mM, 10-350 mM, 10-300 mM, 10-250 mM, 10-200 mM, 10-150 mM, 10-140 mM, 10-130 mM, 10-120 mM, 10-110 mM, 10-100 mM, 10-90 mM, 10-80 mM, 10-70 mM, 10-60 mM, 10-50 mM). In some embodiments, elution from the HA column is accomplished by stepwise increasing the phosphate concentration in the elution buffer. In some embodiments, the stepwise elution buffer may have a phosphate concentration selected from 10 mM, 20 mM, 30 mM, 40 mM, 50 mM, 60 mM, 70 mM, 80 mM, 90 mM, 100 mM, 110 mM, 120 mM, 130 mM, 140 mM, 150 mM, 200 mM, 250 mM, 300 mM, 350 mM, 400 mM. In some embodiments, elution from a mixed-mode chromatography column (e.g., an HA column) is accomplished with an elution buffer having a phosphate (e.g., sodium phosphate) concentration in the range of about 50 mM to about 150 mM (e.g., selected from phosphate (e.g., sodium phosphate) concentrations of about 50 mM, 60 mM, 70 mM, 80 mM, 90 mM, 100 mM, 110 mM, 120 mM, 130 mM, 140 mM, 150 mM, and combinations thereof).

[0096] Many different combinations of conditions for HA chromatography are known and may be used, with the values ​​adjusted to suit the particular protein of interest (e.g., recombinant I2S).

[0097] Hydrophobic interaction chromatography Hydrophobic interaction chromatography (HIC) is a separation technique that uses hydrophobic properties to separate proteins from others. In this type of chromatography, hydrophobic groups such as phenyl, octyl, or butyl are attached to a stationary column. Proteins passing through the column that have hydrophobic amino acid side chains on their surface interact with and bind to the hydrophobic groups on the column. HIC columns are well known and include, for example, phenyl sepharose.

[0098] HIC separations are often designed with conditions opposite to those used for ion exchange chromatography. Usually, a buffer with strong ionic strength, often ammonium sulfate, is applied to the column first. The salts in the buffer reduce the solvation of the sample eluate, and thus the hydrophobic regions that become exposed as the solvation is reduced are absorbed by the medium. The solid phase is usually designed to form hydrophobic interactions with other molecules. The interactions are usually too weak in water, but are made hydrophobic by adding salts (e.g., Na2SO4, K2SO4, (NH4)2SO4, NaCl, NH4Cl, NaBr, and NaSCN) to the buffer. In some embodiments, the mobile phase comprises a salt concentration of about 0.1M to about 3.0M, e.g., about 0.1M to about 1.5M, about 0.2M to about 0.8M, or about 0.3M to about 0.5M.

[0099] In some embodiments, the mobile phase is buffered. In some embodiments, the mobile phase is unbuffered. In some embodiments, the mobile phase is buffered at a pH of about 5 to about 14. In some embodiments, the mobile phase is buffered at a pH of about 5 to about 10. In some embodiments, the mobile phase is buffered at a pH of about 5 to about 7. In some embodiments, the mobile phase is buffered at a pH of about 5.0.

[0100] In some embodiments, the impure preparation or intermediate eluate or flow-through is adjusted to a salt (e.g., NaCl) concentration in the range of about 0.5M to about 2.0M (e.g., about 0.5M, 1.0M, 1.1M, 1.2M, 1.3M, 1.4M, 1.5M, 1.6M, 1.7M, 1.8M, 1.9M, or 2.0M) at a pH of about 4.5 to 6.0 prior to being loaded onto a hydrophobic interaction chromatography column (e.g., a phenyl column). Once loaded, the hydrophobic interaction chromatography column may be washed with a wash buffer containing a salt (e.g., NaCl) concentration in the range of about 0.5M to about 2.0M (e.g., about 0.5M, 1.0M, 1.1M, 1.2M, 1.3M, 1.4M, 1.5M, 1.6M, 1.7M, 1.8M, 1.9M, or 2.0M) at a pH of about 4.5 to 6.0 (e.g., about 4.5, 5.0, 5.5, or 6.0). In some embodiments, a hydrophobic interaction chromatography column may be eluted at a pH of about 4.5 to 6.0 (e.g., about 4.5, 5.0, 5.5, or 6.0) with an elution buffer of about 4.5 to 6.0 (e.g., about 4.5, 5.0, 5.5, or 6.0) containing a salt (e.g., NaCl) concentration in the range of about 0.1 M to about 0.5 M (e.g., about 0.1 M, 0.2 M, 0.3 M, 0.4 M, or 0.5 M).

[0101] Protein characterization of purified I2S Protein characterization of purified I2S may be performed using a variety of methods.

[0102] purity The purity of the purified recombinant I2S protein is typically measured by the levels of various impurities (e.g., host cell proteins or host cell DNA) present in the final product. For example, the level of host cell proteins (HCPs) may be measured by ELISA or SDS-PAGE. In some embodiments, the purified recombinant I2S protein contains less than 150 ng HCPs / mg I2S protein (e.g., less than 140, 130, 120, 110, 100, 90, 80, 70, 60, 50, 40, 30, 30, 20, 10 ng HCPs / mg I2S protein). In some embodiments, the purified recombinant I2S protein does not have new binding with an intensity of more than 0.05%, 0.01%, 0.15%, 0.2%, 0.25%, 0.3%, 0.35%, 0.4%, 0.45%, or 0.5% of the assay control when subjected to silver-stained SDS-PAGE. A variety of assay controls may be used, particularly controls acceptable to regulatory agencies such as the FDA.

[0103] specific activity Purified recombinant I2S protein can be characterized by assessing its functional and / or biological activity. The enzymatic activity of the recombinant I2S composition may be determined using methods well known in the art. Typically, the method involves detecting the removal of sulfate from a synthetic substrate, known as a sulfate release assay. One example of an enzymatic activity assay involves ion chromatography. This method quantifies the amount of sulfate ions enzymatically released by the recombinant I2S from the substrate. The substrate may be a natural or synthetic substrate. In some cases, the substrate is heparin sulfate (e.g., heparin disaccharide), dermatan sulfate, or equivalents. Typically, the released sulfate is analyzed by ion chromatography with a conductivity detector. In the examples, the results are expressed as U / mg of protein, with 1 Unit being defined as the amount of enzyme required to release 1 micromole of sulfate ions from the substrate per hour. In some embodiments, the purified recombinant I2S protein has a specific activity, as measured by an in vitro sulfate release assay using heparin disaccharide as a substrate, in the range of about 0-100 U / mg, about 10-100 U / mg, about 10-80 U / mg, about 20-80 U / mg, about 20-70 U / mg, about 20-60 U / mg, about 20-50 U / mg, about 30-100 U / mg, about 30-90 U / mg, about 30-80 U / mg, about 30-70 U / mg, about 30-60 U / mg, about 40-100 U / mg, about 40-90 U / mg, about 40-80 U / mg, about 40-70 U / mg, or about 40-60 U / mg. In some embodiments, the purified recombinant I2S protein has a specific activity of at least about 5 U / mg, about 10 U / mg, about 15 U / mg, about 20 U / mg, about 25 U / mg, about 30 U / mg, about 35 U / mg, about 40 U / mg, about 45 U / mg, about 50 U / mg, about 55 U / mg, about 60 U / mg, about 65 U / mg, about 70 U / mg, about 75 U / mg, about 80 U / mg, about 85 U / mg, about 90 U / mg, about 95 U / mg, or about 100 U / mg as measured by an in vitro sulfate release assay using heparin disaccharide as a substrate.Exemplary conditions for performing an in vitro sulfate release activity assay using heparin disaccharide as a substrate are provided below. Typically, the assay measures the ability of I2S to release sulfate ions from the naturally derived substrate heparin disaccharide. The released sulfate may be quantified by ion chromatography. In some cases, the ion chromatography is equipped with a conductivity detector. As a non-limiting example, the sample is first buffer exchanged into 10 mM sodium acetate, pH 6 to remove inhibition by phosphate ions in the formulation buffer. The sample is then diluted to 0.075 mg / ml in reaction buffer (10 mM sodium acetate, pH 4.4) and incubated with heparin disaccharide at an enzyme to substrate ratio of 0.3 μg I2S / 100 μg substrate in a reaction volume of 30 μl at 37° C. for 2 hours. The reaction is then stopped by heating the sample to 100° C. for 3 minutes. The analysis is performed using a Dionex IonPac AS18 analytical column with an IonPac AG18 guard column. An isocratic method with 30 mM potassium hydroxide at 1.0 ml / min for 15 min is used. The amount of sulfate released by the I2S samples is calculated from linear regression analysis of sulfate standards in the range of 1.7-16.0 nmoles. Reportable values ​​are expressed as units per mg of protein, with one unit defined as 1 micromole of sulfate released per hour, and protein concentrations are determined by measuring A280.

[0104] In some embodiments, the enzymatic activity of the recombinant I2S protein may also be determined using a variety of other methods known in the art, such as the 4-MUF assay, which measures the hydrolysis of 4-methylumbelliferyl-sulfate to sulfate and the naturally fluorescent 4-methylumbelliferone (4-MUF). In some embodiments, the desired enzymatic activity of the recombinant I2S protein produced is at least 0.5 U / mg, 1.0 U / mg, 1.5 U / mg, 2 U / mg, 2.5 U / mg, 3 U / mg, 4 U / mg, 5 U / mg, 6 U / mg, 7 U / mg, 8 U / mg, 9 U / mg, 10 U / mg, 12 U / mg, 14 U / mg, 16 U / mg, 18 U / mg, or 20 U / mg, as measured by the 4-MUF assay in vitro. In some embodiments, the desired enzymatic activity of the produced recombinant I2S protein, as measured by an in vitro 4-MUF assay, ranges from about 0 to 50 U / mg (e.g., about 0 to 40 U / mg, about 0 to 30 U / mg, about 0 to 20 U / mg, about 0 to 10 U / mg, about 2 to 50 U / mg, about 2 to 40 U / mg, about 2 to 30 U / mg, about 2 to 20 U / mg, about 2 to 10 U / mg, about 4 to 50 U / mg, about 4 to 40 U / mg, about 4 to 30 U / mg, about 4 to 20 U / mg, about 4 to 10 U / mg, about 6 to 50 U / mg, about 6 to 40 U / mg, about 6 to 30 U / mg, about 6 to 20 U / mg, about 6 to 10 U / mg). Exemplary conditions for performing an in vitro 4-MUF assay are provided below. Typically, the 4-MUF assay measures the ability of the I2S protein to hydrolyze 4-methylumbelliferyl-sulfate (4-MUF-SO4) to sulfate and the naturally fluorescent 4-methylumbelliferone (4-MUF). One milliunit of activity is defined as the amount of enzyme required to convert one nanomole of 4-MUF-SO4 to 4-MUF in one minute at 37°C. Typically, the mean fluorescence units (MFU) generated by I2S test samples of known activity can be used to generate a standard curve, which can be used to calculate the enzyme activity of the sample. Specific activity may be calculated by dividing the enzyme activity by the protein concentration.

[0105] In any embodiment, the protein concentration of the recombinant I2S composition may be determined by any suitable method known in the art for determining protein concentration. In some cases, the protein concentration is determined by ultraviolet light absorbance analysis, typically at a wavelength of about 280 nm (A 280 ) will be implemented.

[0106] Charge Characteristics The purified recombinant I2S may be characterized by the charge characteristics associated with the protein. Typically, the protein charge characteristics reflect the pattern of residue side chain charges that typically exist on the surface of the protein. The charge characteristics may be determined by performing an ion exchange (IEX) chromatography (e.g., HPLC) assay of the protein. In some embodiments, "charge characteristics" refers to a set of values ​​that represent the amount of protein that elutes from an ion exchange column at a certain time point after loading a mobile phase containing the exchange ions onto the column.

[0107] Typically, a suitable ion exchange column is an anion exchange column. For example, the charge characteristics may be determined by strong anion exchange (SAX) chromatography using a high performance liquid chromatography (HPLC) system. Typically, recombinant I2S absorbs onto the fixed positive charge of the strong anion exchange column, and a gradient of increasing ionic strength using a mobile phase at a predefined flow rate elutes the recombinant I2S species from the column in proportion to the strength of ionic interaction with the positively charged column. More negatively charged (more acidic) I2S species elute slower than less negatively charged (less acidic) I2S species. The protein concentration of the eluate is detected by ultraviolet light absorption (at 280 nm).

[0108] In some embodiments, recombinant I2S absorbs onto the fixed positive charge of a Mini Q PE column in 20 mM TRIS-HCl at a pH of about 8.0, and a gradient of increasing ionic strength using a mobile phase consisting of 20 mM TRIS-HCl, 1 M sodium chloride, pH 8.0 at a flow rate of 0.8 ml / min elutes the recombinant I2S species from the column in proportion to the strength of the ionic interaction with the positively charged column.

[0109] In some embodiments, the charge profile may be described by a chromatogram of absorbance units versus time after elution from an HPLC column. The chromatogram may include a set of one or more peaks, each peak in the set identifying a subpopulation of recombinant I2S of the composition having a similar surface charge.

[0110] In some embodiments, the purified I2S protein composition exhibits at least six peaks in the charge profile. Exemplary charge profiles of I2S are described in the Examples section and in FIG. 11. As shown in FIG. 11, the six peaks are labeled (A-F) in order of increasing negative charge and decreasing distribution relative to the total peak area of ​​the chromatogram. In some embodiments, the charge profile for the purified recombinant I2S composition includes different numbers, sizes, shapes, or time intervals of the peaks, depending on the amount of negative or positive charges on the surface of the protein. In some embodiments, the recombinant I2S has a charge profile of fewer than six peaks (e.g., fewer than 5, 4, 3, or 2). In some embodiments, the charge profile of the recombinant I2S may have 5, 4, 3, 2, or 1 peak. For example, 1, 2, 3, 4, or 5 peaks A, B, C, D, E, and F may be absent or reduced in the purified recombinant I2S protein composition. Typically, a charge profile is considered to be more homogeneous with fewer peaks.

[0111] Glycan mapping In some embodiments, the purified recombinant I2S protein may be characterized by its proteoglycan composition, typically referred to as glycan mapping. Without wishing to be bound by any theory, it is believed that glycan linkages along with the shape or complexity of the branched structure may affect in vivo clearance, lysosomal targeting, bioavailability, and / or efficacy.

[0112] Typically, the glycan map may be determined by enzymatic digestion and subsequent chromatographic analysis. A variety of enzymes may be used for enzymatic digestion, including, but not limited to, suitable glycosylases, peptidases (e.g., endopeptidases, exopeptidases), proteases, and phosphatases. In some embodiments, a suitable enzyme is alkaline phosphatase. In some embodiments, a suitable enzyme is neuraminidase. Glycans (e.g., phosphoglycans) may be detected by chromatographic analysis. For example, phosphoglycans may be detected by high performance anion exchange chromatography with pulsed amperometric detection (HPAE-PAD) or by particle size exclusion high performance liquid chromatography (HPLC). The amount of glycan (e.g., phosphoglycan) represented by each peak of the glycan map may be calculated using a standard curve of glycan (e.g., phosphoglycan) according to methods well known in the art and disclosed herein.

[0113] In some embodiments, the purified I2S of the present invention exhibits a glycan map comprising seven peak groups, each of which indicates a neutral (peak group 1), monosialylated (peak group 2), disialylated (peak group 3), monophosphorylated (peak group 4), trisialylated (peak group 5), tetrasialylated (peak group 6), or diphosphorylated (peak group 7) I2S protein. An exemplary I2S glycan map is depicted in FIG. 10. In some embodiments, the purified recombinant I2S has a glycan map with fewer than seven groups (e.g., 6, 5, 4, 3, or 2 peak groups). In some embodiments, the purified recombinant I2S has a glycan map with seven or more peak groups (e.g., 8, 9, 10, 11, 12, or more).

[0114] The relative amount of glycan corresponding to each peak group may be determined based on the peak group relative to the corresponding peak group area of ​​the predetermined standard sample. In some embodiments, peak group 1 (neutral) has a peak area in the range of about 40-120% (e.g., about 40-115%, about 40-110%, about 40-100%, about 45-120%, about 45-115%, about 45-110%, about 45-105%, about 45-100%, about 50-120%, about 50-110%) with respect to the corresponding peak group area of ​​the standard sample. In some embodiments, peak group 2 (monosialylated) has a peak area in the range of about 80-140% (e.g., about 80-135%, about 80-130%, about 80-125%, about 90-140%, about 90-135%, about 90-130%, about 90-120%, about 100-140%) of the corresponding peak group area of ​​the standard sample. In some embodiments, peak group 3 (disialylated) has a peak area in the range of about 80-110% (e.g., about 80-105%, about 80-100%, about 85-105%, about 85-100%) of the corresponding peak group area of ​​the standard sample. In some embodiments, peak group 4 (monophosphorylated) has a peak area in the range of about 100-550% (e.g., about 100-525%, about 100-500%, about 100-450%, about 150-550%, about 15-500%, about 150-450%, about 200-550%, about 200-500%, about 200-450%, about 250-550%, about 250-500%, about 250-450%, or about 250-400%) relative to the corresponding peak group area of ​​the standard sample. In some embodiments, peak group 5 (trisialylation) has a peak area in the range of about 70-110% (e.g., about 70-105%, about 70-100%, about 70-95%, about 70-90%, about 80-110%, about 80-105%, about 80-100%, or about 80-95%) of the corresponding peak group area of ​​the standard sample. In some embodiments, peak group 6 (tetrasialylation) has a peak area in the range of about 90-130% (e.g., about 90-125%, about 90-120%, about 90-115%, about 90-110%, about 100-130%, about 100-125%, or about 100-120%) of the corresponding peak group area of ​​the standard sample.In some embodiments, peak group 7 (diphosphorylation) has a peak area in the range of about 70-130% (e.g., about 70-125%, about 70-120%, about 70-115%, about 70-110%, about 80-130%, about 80-125%, about 80-120%, about 80-115%, about 80-110%, about 90-130%, about 90-125%, about 90-120%, about 90-115%, about 90-110%) relative to the corresponding peak group area of ​​the standard sample. A variety of glycan mapping standards are known in the art and can be used to practice the present invention. Typically, peak group 7 (diphosphorylation) corresponds to the level of di-M6P on the surface of purified recombinant I2S protein.

[0115] The glycosylation pattern of purified I2S influences lysosomal targeting. Various in vitro cellular uptake assays are known in the art and can be used to practice the present invention. For example, to assess I2S uptake by M6P receptors, cellular uptake assays are performed using human fibroblasts expressing M6P receptors on their surface. The amount of internalized I2S can be measured by ELISA. In some embodiments, the purified recombinant I2S protein of the present invention is characterized by greater than 70%, 75%, 80%, 85%, 90%, 95% cellular uptake as determined by in vitro cellular uptake assays.

[0116] Peptide mapping In some embodiments, peptide mapping may be used to characterize amino acid composition, post-translational modifications, and / or cellular processing such as signal peptide cleavage, formylglycine conversion, and / or glycosylation. Typically, recombinant proteins may be cleaved into distinct peptide fragments, either by controlled or random cleavage, to generate patterns or peptide maps. In some cases, purified I2S proteins may be first subjected to enzymatic digestion before analysis. Digestion may be performed using peptidases, glycosides, hydrolases, phosphatases, lipases, or proteases and / or combinations thereof before analysis. The structural composition of peptides may be determined using methods well known in the art. Exemplary methods include, but are not limited to, mass spectrometry, nuclear magnetic resonance (NMR), or HPLC.

[0117] Conversion rate of formylglycine Peptide mapping was used to determine the FGly conversion rate. I2S activity requires a cysteine ​​(corresponding to position 59 of mature human I2S) for formylglycine conversion by formylglycine generating enzyme (FGE), as shown below. [ka] Therefore, the formylglycine conversion (% FG) can be calculated using the following formula:

number

[0118] To calculate %FG, recombinant I2S protein may be digested into short peptides using proteolytic enzymes (e.g., trypsin or chymotrypsin). The short peptides are separated and characterized using size exclusion high performance liquid chromatography (HPLC). Peptides containing a position corresponding to position 59 of mature human I2S were characterized for whether Cys at position 59 is converted to FGly compared to a control (e.g., I2S protein without FGly conversion or I2S protein with 100% FGly conversion). The amount of peptides containing FGly (corresponding to the number of active I2S molecules) and the total amount of peptides with both FGly and Cys may be determined based on the corresponding peak areas, and a ratio reflecting %FG can be calculated.

[0119] In some embodiments, a purified recombinant I2S protein of the invention has at least 70% (e.g., at least about 77%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%) conversion of the cysteine ​​residue corresponding to Cys59 of human I2S (SEQ ID NO:1) to Cα-formylglycine (FGly). In some embodiments, a purified recombinant I2S protein of the invention has substantially 100% conversion of the cysteine ​​residue corresponding to Cys59 of human I2S (SEQ ID NO:1) to Cα-formylglycine (FGly).

[0120] Sialic acid content In some embodiments, the purified recombinant I2S protein is characterized by its sialic acid composition. Without wishing to be bound by theory, it is understood that sialic acid residues on proteins can prevent, reduce or inhibit rapid in vivo clearance by asialoglycoprotein receptors present in hepatocytes. Thus, recombinant proteins with relatively high sialic acid content are typically expected to have relatively long circulation times in vivo.

[0121] In some embodiments, the amount of sialic acid in the purified recombinant I2S protein may be determined using methods well known in the art. For example, the amount of sialic acid in the purified I2S protein may be determined by enzymatic digestion and subsequent chromatographic analysis. Any suitable sialidase may be used to achieve the enzymatic digestion. In some cases, digestion is performed by a glycoside hydrolase enzyme, such as neuraminidase. Sialic acid may be determined by chromatographic analysis, such as, for example, high performance anion exchange chromatography with amperometric electrochemical detection (HPAE-PAD). The amount of sialic acid in the recombinant I2S composition may be calculated using a standard curve of sialic acid according to methods well known in the art and described herein.

[0122] In some embodiments, the amount of sialic acid in the purified recombinant I2S protein is greater than 16 mol / mol. In the context of the amount of sialic acid, "mol / mol" refers to the number of moles of sialic acid residues per mole of enzyme. In some cases, the amount of sialic acid in the recombinant I2S protein is about 16.5 mol / mol, about 17 mol / mol, about 18 mol / mol, about 19 mol / mol, about 20 mol / mol, about 21 mol / mol, about 22 mol / mol or more, or more. In some embodiments, the amount of sialic acid in the purified recombinant I2S protein can be in the range of about 16-20 mol / mol, 16-21 mol / mol, about 16-22 mol / mol, 16-23 mol / mol, 16-24 mol / mol, about 16-25 mol / mol, about 17-20 mol / mol, 17-21 mol / mol, about 17-22 mol / mol, 17-23 mol / mol, 17-24 mol / mol, or about 17-25 mol / mol.

[0123] Pharmaceutical Compositions and Administration The purified recombinant I2S protein can be administered to a Hunter syndrome patient according to known methods. For example, the purified recombinant I2S protein can be delivered intravenously, subcutaneously, intramuscularly, parenterally, transdermally, or mucosally (e.g., orally or nasally).

[0124] In some embodiments, the recombinant I2S or a pharmaceutical composition containing it is administered to the subject by intravenous administration.

[0125] In some embodiments, the recombinant I2S or pharmaceutical composition containing it is administered to a subject by intrathecal administration. As used herein, the term "intrathecal administration" or "intrathecal injection" refers to injection into the spinal canal (the subarachnoid space surrounding the spinal cord). Various techniques may be used, including, but not limited to, lateral ventricular injection via a burr hole or cisternal puncture or lumbar puncture, etc. In some embodiments, "intrathecal administration" or "intrathecal delivery" according to the present invention refers to IT administration or delivery via the lumbar region or area, i.e., lumbar IT administration or delivery. As used herein, the term "lumbar region" or "lumbar region" refers to the third and fourth lumbar vertebrae (lower back), more generally the L2-S1 region of the spine.

[0126] In some embodiments, recombinant I2S or a pharmaceutical composition containing it is administered to a subject by subcutaneous (i.e., under the skin) administration. For such purposes, the formulation may be injected using a syringe. However, other devices are available for administration of the formulation, such as, for example, injection devices (Inject-ease™ Genject™ devices); injection pens (e.g., GenPen™); needleless devices (e.g., MediJector™ and BioJector™); and subcutaneous attachment delivery systems.

[0127] In some embodiments, intrathecal administration may be used in combination with other routes of administration (e.g., intravenous, subcutaneous, intramuscular, parenteral, transdermal, or transmucosal (e.g., oral or nasal)).

[0128] The present invention contemplates single as well as multiple administrations of a therapeutically effective amount of recombinant I2S or a pharmaceutical composition containing the same as described herein. The recombinant I2S or a pharmaceutical composition containing the same can be administered at regular intervals depending on the nature, severity and extent of the subject's condition (e.g., lysosomal storage disease). In some embodiments, a therapeutically effective amount of recombinant I2S or a pharmaceutical composition containing the same can be administered periodically at regular intervals (e.g., once a year, once every 6 months, once every 5 months, once every 3 months, once every 2 months (once every 2 months), once a month (once every month), once every 2 weeks (once every 2 weeks), weekly, daily or continuously).

[0129] The recombinant I2S or a pharmaceutical composition containing it can be formulated with a physiologically acceptable carrier or excipient to prepare a pharmaceutical composition. The carrier and the therapeutic agent can be sterile. The formulation should be suitable for the mode of administration.

[0130] Suitable pharma- ceutically acceptable carriers include, but are not limited to, water, salt solutions (e.g., NaCl), saline, buffered saline, alcohols, glycerol, ethanol, gum arabic, vegetable oils, benzyl alcohol, polyethylene glycol, gelatin, carbohydrates such as lactose, amylose, or starch, sugars such as mannitol, sucrose, etc., dextrose, magnesium stearate, talc, silicic acid, viscous paraffin, aromatic oils, fatty acid esters, hydroxymethylcellulose, polyvinylpyrrolidone, etc., as well as combinations thereof. If desired, the pharmaceutical preparations can be mixed with auxiliary substances (e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorants, flavorings, and / or aromatic substances, etc.) that do not adversely react with the active compounds or interfere with their activity. In some embodiments, water-soluble carriers suitable for intravenous administration are used.

[0131] The composition or drug can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents, if desired. The composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder. The composition can also be formulated as a suppository with a conventional binder or carrier, such as triglyceride. Oral formulations can include standard carriers, such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, polyvinylpyrrolidone, sodium saccharin, cellulose, magnesium carbonate, etc.

[0132] The composition or drug can be formulated according to routine procedures as a pharmaceutical composition suitable for administration to humans. For example, in some embodiments, a composition for intravenous administration is usually a solution in an isotonic aqueous buffer. If necessary, the composition can contain a solubilizing agent and a local anesthetic to reduce pain at the site of injection. Generally, the ingredients are supplied separately or mixed together in unit dosage form, for example, as a lyophilized powder or water-free concentrate in a sealed container such as an ampoule or sachet indicating the quantity of active agent. If the composition is to be administered by infusion, it can be dispensed in an infusion bottle containing sterile pharmaceutical grade water, saline or dextrose / water. If the composition is to be administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients can be mixed prior to administration.

[0133] As used herein, the term "therapeutically effective amount" is determined primarily based on the total amount of therapeutic agent contained in the pharmaceutical composition of the present invention. In general, a therapeutically effective amount is sufficient to achieve a meaningful benefit to the subject (e.g., treating, regulating, curing, preventing and / or ameliorating the underlying disease or condition). For example, a therapeutically effective amount may be an amount sufficient to achieve a desired therapeutic and / or prophylactic effect, such as an amount sufficient to modulate a lysosomal enzyme receptor or its activity, thereby treating a lysosomal storage disease or its symptoms (e.g., reducing or eliminating the presence or occurrence of "zebra bodies" or cellular vacuolar degeneration following administration of the composition of the present invention to the subject). In general, the amount of therapeutic agent (e.g., recombinant lysosomal enzyme) administered to a subject in need thereof will depend on the characteristics of the subject. Such characteristics include the subject's condition, disease severity, general condition, age, sex and weight. Those skilled in the art will be able to easily determine the appropriate dosage depending on these and related factors. In addition, both objective and subjective assays may be optionally employed to identify optimal dosage ranges.

[0134] A therapeutically effective amount is generally administered in a dosing regimen comprising multiple unit doses. For a particular therapeutic protein, the therapeutically effective amount (and / or appropriate unit dose within an effective dosing regimen) may vary, for example, depending on the route of administration, the use in combination with other pharmaceutical agents. The specific therapeutically effective amount (and / or unit dose) for a particular patient may also depend on a variety of factors, including the disorder being treated and the severity of the disorder, the activity of the specific pharmaceutical agent employed, the specific composition employed, the age, weight, general condition, sex and diet of the patient, the time of administration, the route of administration and / or the rate of excretion or metabolism of the specific fusion protein employed, the duration of treatment, and similar factors as are well known in the medical art.

[0135] Additional exemplary pharmaceutical compositions and methods of administration are described in PCT Publication WO2011 / 163649, entitled "Methods and Compositions for CNS Delivery of Iduronate-2-Sulfatase," and Provisional Patent Application No. 61 / 618,638, entitled "Subcutaneous Administration of Iduronate-2-Sulfatase," both of which were filed on March 30, 2012, the entire disclosures of which are incorporated herein by reference.

[0136] It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of enzyme replacement therapy, and that dosage ranges set forth herein are exemplary only and are not intended to limit the scope of the practice of the invention as claimed. EXAMPLES

[0137] Example 1: Recombinant I2S AF capture and purification process This example illustrates that a simplified downstream purification process may be used to capture and purify recombinant I2S produced in serum-free medium. An exemplary purification scheme is depicted in FIG.

[0138] A cell line was developed that stably expresses the iduronate 2-sulfatase enzyme (I2S) and formylglycine generating enzyme (FGE). The development and characterization of an exemplary cell line is described in U.S. Provisional Patent Application "Cells for Producing Human Iduronate 2-Sulfatase" (the filing date of which is set forth in the specification), which is incorporated herein by reference in its entirety. Briefly, a human cell line was engineered to co-express the human I2S protein with the amino acid sequence set forth in SEQ ID NO:2 and the human formylglycine generating enzyme (FGE) set forth in SEQ ID NO:5. SEQ ID NO:2 Full-length precursor iduronate 2-sulfatase: MPPPRTGRGLLWLGLVLSSVCVALGSETQANSTTDALNVLLIIVDDLRPSLGCYGDKLVRSPNIDQLASHSLLFQNAFAQQAVCAPSRVSFLTGRRPDTTRLYDFNSYWRVHAGNFSTIPQYFKENGYVTMSVGKVF HPGISSNHTDDSPYSWSFPPYHPSSEKYENTKTCRGPDGELHANLLCPDVLDVPEGTLPDKQSTEQAIQLLEKMKTSASPFFLAVGYHKPHIPFRYPKEFQKLYPLENITLAPDPEVPDGLPPVAYNPWMDIRQRED VQALNISVPYGPIPVDFQRKIRQSYFASVSYLDTQVGRLLSALDDLQLANSTIIAFTSDHGWALGEHGEWAKYSNFDVATHVPLIFYVPGRTASLPEAGEKLFPYLDPFDSASQLMEPGRQSMDLVELVSLFPTLAG LAGLQVPPRCPVPSFHVELCREGKNLLKHFRFRDLEEDPYLPGNPRELIAYSQYPRPSDIPQWNSDKPSLKDIKIMGYSIRTIDYRYTVWVGFNPDEFLANFSDIHAGELYFVDSDPLQDHNMYNDSQGGDLFQLLMP SEQ ID NO:5 Full-length human FGE precursor: MAAPALGLVCGRCPELGLVLLLLLLSLLCGAAGSQEAGTGAGAGSLAGSCGCGTPQRPGAHGSSAAAHRYSREANAPGPVPGERQLAHSKMVPIPAGVFTMGTDDPQIKQDGEAPARRVTIDAFYMDAYEVSNTEFEKFVNSTGYLTEAEKFGDSFVFEGMLSEQVKTNIQQAVAAAPWWLPVKGAN WRHPEGPDSTILHRPDHPVLHVSWNDAVAYCTWAGKRLPTEAEWEYSCRGGLHNRLFPWGNKLQPKGQHYANIWQGEFPVTNTGEDGFQGTAPVDAFPPNGYGLYNIVGNAWEWTSDWWTVHHSVEETLNPKGPPSGKDRVKKGGSYMCHRSYCYRYRCAARSQNTPDSSASNLGFRCAADRLPTMD

[0139] After synthesis of the full-length I2S enzyme, the 25 amino acid signal peptide was removed and the soluble mature I2S enzyme was secreted from the cells.

[0140] Chemically defined media (serum-free / animal component-free; AF) was used for the bioreactor process.

[0141] The volume of the individual harvested materials was reduced and the buffer exchanged by ultrafiltration / diafiltration process. The material, called unpurified bulk (UPB), was frozen at -50°C for each individual harvest. The downstream purification process started with dissolution and pooling of the unpurified bulk, followed by successive viral inactivation, anion exchange (Capto Q), mixed mode (ceramic hydroxyapatite), cation exchange (SP Sepharose) and hydrophobic interaction (phenyl Sepharose) chromatography steps, followed by viral filtration, and final concentration and diafiltration steps. In particular, the purification process used Q, hydroxyapatite, SP and phenyl chromatography modes. Protein G and size exclusion chromatography, traditionally used in I2S purification processes, were eliminated. Exemplary steps are shown in Table 3. [Table 3-1] [Table 3-2]

[0142] The purity of the purified I2S protein was assessed by peptide mapping, SDS-PAGE (silver) and size exclusion HPLC. Enzyme specific activity, formylglycine content, sialic acid content, glycan map and charge characteristics were determined using standard methods. Exemplary results are shown in Table 4. [Table 4-1]

Table 4-2

[0143] An exemplary peptide map when compared to a commercially available I2S reference is shown in Figure 2. The results of an exemplary SDS-PAGE (silver) analysis are shown in Figure 3. Typically, using the processes described herein, the HCP concentration (DS) of the drug substance is <100 ppm, meeting the <100 ppm specification required in many markets including the United States. The SEC of DS is ≧99.5%, also meeting the current >99.3% required in many markets. Exemplary charge characteristics are shown in Figure 4. An exemplary glycan map is shown in Figure 5. In particular, the glycan map of purified I2S contains seven peak groups, eluting according to the increasing amount of negative charge arising from sialic acid and mannose 6-phosphate residues, in order, elution, neutral, mono, disialylated, monophosphorylated, trisialylated, and hybrid (monosialylated and capped M6P), tetrasialylated, and hybrid (disialylated and capped M6P) and diphosphorylated glycans.

[0144] In summary, the examples demonstrate that the purified I2S can be successfully purified on a large scale in a xeno-free medium using a simplified four-column purification process.

[0145] Example 2: Recovery of Recombinant I2S AF and Stability Tests for Virus Inactivation The objective of this implementation right is to evaluate the effects of temperature holding time and freeze-thaw cycles on the stability of the purified recovered recombinant I2S.

[0146] The purified recovered samples were stored at ambient and 2 - 8°C for up to 7 days, and the virus-inactivated UPB samples were stored at ambient for up to 24 hours. The freeze-thaw samples of the purified recovery were frozen at -20°C, -50°C, and -80°C, and up to 3 cycles of freeze-thaw were performed. Western blot, SEC HPLC, and activity assays were used to measure stability.

[0147] I2S-AF harvest material was produced from 2D cell lines by CCPD at the desired flow rate using a B. Braun 20L bioreactor equipped with a centrifuge retention device. For temperature retention studies, each clarified harvest was stored at ambient and 2-8 °C and harvested at the selected retention time. Sampling volumes and retention times are listed in Table 5. Freeze-thaw samples were stored at -20 °C, -50 °C, and -80 °C and thawed at 25 °C using a water bath. [Table 5]

[0148] A viral inactivation step occurred on the crude bulk step before loading onto the first column. UPB was produced by buffer exchange of the concentrated and clarified harvest. UF / DF was performed using a Pall 1 sq.ft. Centramate system and buffer were exchanged to 10 mM MES, 155 mM NaCl, pH=6.5. The viral inactivation step was performed by adding 1% Tween 80 and 0.3% TnBP and filtering using Durapor syringe filters at each time point. Samples were removed at each time point listed in Table 6 and frozen at -80°C. Samples from the retention points of the clarified harvest and freeze-thaw testing were performed by Western blot and activity (4-MUF assay). UPB samples from viral inactivation were tested for purity by SEC HPLC. Activity results of retention points from harvests 12 and 18 in Table 5 showed no significant changes in atmosphere and storage at 2-8°C for up to 7 days for both harvests. No significant changes in activity of harvest 12 were observed during up to three freeze-thaw cycles stored at -20°C, -50°C, and -80°C. [Table 6]

[0149] The activity and SEC-HPLC for the stability of the viral inactivation UPB step are presented in Figures 6 and 7. It is shown that there were no issues with the stability of the viral inactivation based on activity and purity up to 24 hours.

[0150] In summary, based on the stability analyses described herein, the clarified harvest can be stored at 2-8°C (e.g., for up to 7 days) without significant changes in harvest quality. The clarified harvest can be subjected to multiple freeze-thaw cycles and stored at -20°C, -50°C, and -80°C without significant changes in stability. Based on the SEC HPLC purity results, viral inactivation at the UPB step can be performed at ambient temperature (e.g., for up to 24 hours) without any changes in activity and purity.

[0151] Example 3: Purification and analysis of animal-free IL-CD media

[0152] The objective of this study was to purify from a pooled harvest of I2S-AF produced by animal-free perfusion using a chemically defined medium and to characterize the drug substance.

[0153] The study evaluated the performance of the I2S-AF purification process and drug substance (DS) produced from a chemically defined medium bioreactor.

[0154] Cell culture media I2S-AF material was produced from cell line 2D expressing I2S and formylglycine generating enzyme (FGE) as described in Example 1. Material was produced in a 1 L Das Gip spin filter bioreactor at CCPD using a defined serum-free medium. Individual bags from each of the clarified harvests (HI-21) were received, frozen at -20°C, and thawed overnight at 2-8°C. Equal amounts of each of the clarified harvests were pooled, representing the total harvest pool, and then 0.2 μm filtered to a total membrane area of ​​1 ft 2The unpurified bulk (UPB) was filtered through a 0.2 μm filter and frozen prior to use.

[0155] purification Exemplary column specifications and loads are described in Table 7. Q Sepharose was loaded by titer with a target of 3 g / L. The next column was loaded at 100% from the previous column eluate and no material was removed. [Table 7]

[0156] A single purification was performed from the bioreactor using pooled UPB from harvests 1 to 21. UPB was thawed overnight at 2-8°C and pooled in equal amounts from each harvest.

[0157] The process steps and buffer formulations for the individual columns can be seen in Tables 8-11. Prior to loading onto the Q Sepharose FF column, the pooled UPB was filtered using a 0.2um bottle filter system, the pH was adjusted to 6.5 using 1M sodium acetate, and the conductivity was adjusted to 16mS / cm with 5M sodium chloride. Prior to loading onto the HA column, the Q Sepharose elution was adjusted to 0.001M NaP04 using 0.25M NaP04, pH 5.5, and filtered through a 0.22um PES bottle top filter. The HA elution conductivity was adjusted to 1.55M NaCl with 5M NaCl, and pH was adjusted to 5.5 with 1M sodium acetate. The conditioning time was approximately 1 hour. Prior to loading onto the Phenyl Sepharose column, the conditioned pool was filtered using a 0.22um PES bottle top filter. The phenyl eluate was concentrated 4-fold and diafiltered six times into 0.02 M NaP04, 0.137 M NaCl, pH 6.0. The diafiltered product was adjusted to 2.0 g / L and formulated with 0.2% polysorbate 20 to generate simulated drug substance. A simulated pool of H1-20 of DS was generated for further characterization. [Table 8] [Table 9] [Table 10] [Table 11]

[0158] In-process purification by HCLP with ELISA Table 12 describes the in-process HOP removal for each step. In-process HCLP results showed the majority of removal was high at the HA step. [Table 12]

[0159] Characterization of drug substances The release results of an exemplary drug substance lot are listed in Table 13. As can be seen, the drug substance had high specific activity and %FG in the purified material. Characterization of the exemplary drug substance attributes is shown in Table 13. HCP was reduced from 1,870 ng / mg to 372 ng / mg in the final UF / DF step. [Table 13-1] [Table 13-2]

[0160] Example 4: Physiochemical and biological characterization of purified recombinant I2S enzyme The aim of the Examples is to provide a detailed characterization of recombinant I2S protein purified using the methods described above.

[0161] SDS-PAGE For the experiment, recombinant I2S protein was generated using 2D and 4D human cell lines in two separate serum-free culture medium reactions. Samples were harvested and purified using the methods described above. The purified I2S enzyme was analyzed by SDS-PAGE and silver stained for visualization. Exemplary results are shown in FIG. 8. As shown in FIG. 8, recombinant I2S protein purified using the methods described herein showed comparable horizontal stripes compared to an I2S standard sample purified using standard methods.

[0162] Peptide Map The recombinant I2S protein produced from I2S-AF 2D cell line was purified as described above. The purified recombinant I2S and reference human I2S samples were each subjected to proteolytic digestion and examined by HPLC analysis. The exemplary peptide map is shown in Figure 9 when compared with the peptide map of reference I2S.

[0163] Conversion rate of formylglycine Peptide mapping was used to determine the FGly conversion rate. I2S activity requires a cysteine ​​(corresponding to position 59 of mature human I2S) for formylglycine conversion by formylglycine generating enzyme (FGE), as shown below. [ka] Therefore, the formylglycine conversion (% FG) can be calculated using the following formula:

number

[0164] For example, a FG of 50% means that half of the purified recombinant I2S is enzymatically inactive without any therapeutic effect.

[0165] Peptide mapping was used to calculate %FG. Briefly, purified recombinant I2S protein was digested into short peptides using proteolytic enzymes (e.g., trypsin or chymotrypsin). The short peptides were separated and characterized using HPLC. Peptides containing a position corresponding to position 59 of mature human I2S were characterized for whether Cys at position 59 was converted to FGly compared to a control (e.g., I2S protein without FGly conversion or I2S protein with 100% FGly conversion). The amount of peptides containing FGly (corresponding to the number of active I2S molecules) and the total amount of peptides with both FGly and Cys may be identified based on the corresponding peak areas, and a ratio reflecting %FG was calculated. Exemplary results are shown in Table 14.

[0166] Glycan map - Mannose 6-phosphate and sialic acid content The glycan and sialic acid composition of the purified recombinant I2S protein was determined. Anion exchange chromatography was used to quantify the glycan composition and generate a glycan map. As described below, the glycan map of recombinant I2S purified under the conditions described herein consists of seven peaks that elute according to increasing amounts of negative charge and are at least partially derived from sialic acid and mannose-6-phosphate glycoforms resulting from the enzymatic digest. Briefly, recombinant I2S and reference recombinant I2S purified from serum-free cell cultures (I2S-AF 2D serum-free and I2S-AF 4D serum-free) were treated with either (1) purified neuraminidase enzyme (Arthrobacter ureafaciens (10 mU / μL), Roche Biochemical (Indianapolis, IN), catalog no. 269 611 (1U / 100 μL)) to remove sialic acid residues, (2) alkaline phosphatase to completely release mannose-6-phosphate residues, (3) alkaline phosphatase + neuraminidase, or (4) no treatment at 37 ± 1 °C for 2 h. Each enzymatic digest was analyzed by Anion Exchange Chromatography with Pulsed Amperometric Detection (HPAE-PAD) using a CarboPac PA1 Analytical Column with a Dionex CarboPac PA1 Guard Column. Sialic acid and mannose-6-phosphate standards ranging from 0.4 to 2.0 nmoles were run for each assay. Isocratic runs were performed using 48 mM sodium acetate in 100 mM sodium hydroxide at ambient column temperature with a flow rate of 1.0 mL / min for a minimum of 15 minutes to elute each peak. Data generated from the individual runs for both the I2S-AF and I2S standards were each combined into a single chromatograph to represent the glycan map for each individual recombinant protein.As shown in Figure 10, the glycan map of I2S purified from serum-free medium shows representative elution peaks (in order of elution) consisting of neutral, mono-, disialylated, monophosphorylated, trisialylated, and hybrid (monosialylated and capped mannose-6-phosphate), tetrasialylated, and hybrid (disialylated and capped mannose-6-phosphate) and diphosphorylated glycans. An exemplary glycan map is shown in Figure 10.

[0167] The average amount of sialic acid (moles sialic acid per mole protein) for each recombinant I2S sample was calculated from linear regression analysis of the sialic acid standards. PeakNet6 software was used to visualize each chromatogram run. Sialic acid standards and sialic acid released from recombinant I2S assay control and test samples appear as a single peak. The amount of sialic acid (nanomoles) for I2S was calculated as a raw value using the following formula:

number

number

[0168] Exemplary data indicating the amount of sialic acid on recombinant I2S purified from I2S-AF 2D or 4D cell lines is shown in Table 14. [Table 14-1] [Table 14-2]

[0169] specific activity The specific activity of recombinant I2S enzymes purified using the methods described herein was analyzed using an in vitro sulfate release assay or a 4-MUF assay.

[0170] In vitro sulfate assay An in vitro sulfate assay was performed using heparin disaccharide as a substrate. Specifically, the assay measures the ability of I2S to release sulfate ions from the naturally occurring substrate heparin disaccharide. The released sulfate may be quantified by ion chromatography with a conductivity detector. Briefly, samples were first buffer exchanged into pH 6, 10 mM Na acetate to remove inhibition by phosphate ions in the buffer formulation. Samples were then diluted to 0.075 mg / ml in reaction buffer (10 mM Na acetate, pH 4.4) and incubated for 2 hours at 37°C with a substrate ratio of 0.3 μg I2S / 100 μg enzyme substrate heparin disaccharide in a reaction volume of 30 μL. The reaction was stopped by heating the samples at 100°C for 3 minutes. Analysis was performed using a Dionex IonPac AS18 analytical column with an IonPac AG18 guard column. An isocratic method was used with 30 nM potassium hydroxide at 1.0 mL / min for 15 min. The amount of sulfate released by the I2S samples was calculated from linear regression analysis of sulfate standards ranging from 1.7 to 16.0 nmoles. Reportable values ​​are expressed as units of protein per mg, with one unit defined as 1 micromole of sulfate released per hour, and protein concentrations were determined by A280 measurements. Exemplary results are presented in Table 14.

[0171] 4-MUF assay The specific activity of purified recombinant I2S enzyme may also be analyzed using a fluorescence-based 4-MUF assay. Briefly, the assay measures the hydrolysis of the I2S substrate 4-methylumbelliferyl-sulfate (4-MUF-SO4). When the 4-MUF-SO4 substrate is cleaved by I2S, the molecule is converted to sulfate and the naturally fluorescent 4-methylumbelliferone (4-MUF). As a result, I2S enzyme activity can be determined by evaluating the overall change in the fluorescent signal over time. For the experiments, purified I2S enzyme produced from I2S-AF 2D and 4D human cell lines was incubated with a solution of 4-methylumbelliferyl-sulfate (4-MUF-SO4), potassium salt (Sigma catalog number M-7133). The assay was calibrated using a series of control standards and using commercially available I2S enzyme diluted 1:100, 1:200 and 1:20,000 from the stock solution. The enzyme assay was performed at 37° C. and analyzed using a calibrated fluorometer. For each standard sample, the resulting fluorescence values ​​were used to determine the percent coefficient of variation using the following equation:

number

[0172] To determine reportable enzyme activity, the rate CV values ​​were then used to calculate the corrected mean fluorescence for each sample and expressed in mU / mL using the following formula:

number

[0173] One milliunit of activity is the amount of enzyme required to convert 1 nmole of 4-methylumbelliferyl sulfate to 4-methylumbelliferone in 1 minute at 37°C.

[0174] Charge Characteristics In this experiment, the charge distribution of each purified recombinant I2S was determined by strong anion exchange (SAX) chromatography with high performance liquid chromatography (HPLC). This method separates recombinant I2S variants within a sample based on surface charge differences. At pH 8.00, negatively charged species are absorbed onto the fixed positive charges of the SAX column. A gradient of increasing ionic strength is used to elute each protein species in proportion to the strength of ionic interaction with the column. One hundred micrograms of purified I2S isolated from 2D cell lines or reference recombinant I2S enzymes under serum-free growth conditions were loaded onto an Amersham Biosciences Mini Q PE (4.6x50mm) column held at ambient temperature and equilibrated to 20mM Tris-HCl, pH 8.00. Gradient elution was performed at a flow rate of 0.80mL / min using a mobile phase of 20mM Tris-HCl, 1.0M sodium chloride, pH 8.00. Protein concentrations were determined continuously during the run by measuring the absorbance of the sample elution at a wavelength of 280 nm. Exemplary results of charge profiles observed for recombinant I2S purified from 2D and 4D cell lines are shown in FIG.

Claims

1. A composition for preventing or treating Mucopolysaccharidosis Type II (MPSII, Hunter Syndrome), comprising a purified recombinant iduronate-2-sulfatase (I2S) having the amino acid sequence of SEQ ID NO:1, The purified recombinant I2S contains at least about 70% molar conversion of cysteine ​​residues corresponding to Cys59 of SEQ ID NO:1 to Cα-formylglycine (FGly); and Further, the purified recombinant I2S contains, on average, at least 16 sialic acids per molecule, and the composition is produced by a cell line selected from NSO / 1, PER.C6, COS-7, HEK293, HT1080, BHK21, CHO, TM4, CV1 ATCC CCL 70, VERO-76, HeLa, MDCK, BRL 3A, W138, Hep G2, MMT 060562, TRI cells, MRC 5 cells, FS4 cells, and Hep G2.

2. The composition of claim 1, wherein the purified recombinant I2S contains, on average, at least 18 sialic acids per molecule.

3. The composition of claim 1, wherein the purified recombinant I2S contains, on average, at least 20 sialic acids per molecule.

4. The composition of any one of claims 1 to 3, wherein the purified recombinant I2S comprises at least a 75% molar conversion of cysteine ​​residues corresponding to Cys59 of SEQ ID NO:1 to Cα-formylglycine (FGly).

5. The composition of any one of claims 1 to 3, wherein the purified recombinant I2S comprises at least an 80% molar conversion of cysteine ​​residues corresponding to Cys59 of SEQ ID NO:1 to Cα-formylglycine (FGly).

6. 4. The composition of any one of claims 1 to 3, wherein the purified recombinant I2S comprises greater than 85% molar conversion of cysteine ​​residues corresponding to Cys59 of SEQ ID NO:1 to Cα-formylglycine (FGly).

7. 4. The composition of any one of claims 1 to 3, wherein the purified recombinant I2S comprises greater than 90% molar conversion of cysteine ​​residues corresponding to Cys59 of SEQ ID NO:1 to Cα-formylglycine (FGly).

8. 4. The composition of any one of claims 1 to 3, wherein the purified recombinant I2S comprises greater than 95% molar conversion of cysteine ​​residues corresponding to Cys59 of SEQ ID NO:1 to Cα-formylglycine (FGly).

9. The composition of any one of claims 1 to 3, wherein the purified recombinant I2S comprises 100% molar conversion of the cysteine ​​residue corresponding to Cys59 of SEQ ID NO:1 to Cα-formylglycine (FGly).

10. The composition of any one of claims 1 to 9, wherein the purified recombinant I2S is free of host cell proteins (HCPs), or the purified recombinant I2S is free of HCPs and the amount of HCPs is less than 100 ng / mg.

11. A formulation comprising the composition of any one of claims 1 to 10 and a physiologically acceptable carrier.

12. 12. The formulation of claim 11, suitable for intravenous administration.

13. 12. The formulation of claim 11, suitable for intrathecal administration.

14. 12. The formulation of claim 11, suitable for subcutaneous administration.

15. The formulation of claim 11 for treating Hunter syndrome.

Citation Information

Patent Citations

  • Mucosal adjuvant composition

    WO2012042857A1